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Ceramide forms a novel type of channel in the mitochondrial outer 
membrane and these channels are involved the release of intermembrane space 
proteins from mitochondria, a decision-making step in the apoptotic process. 
An antiapoptotic protein, Bcl-xL, regulates the apoptotic process and inhibits 
the formation of ceramide channels. However, there is no precedent to indicate 
how a protein regulates a lipid channel. We investigated the mechanism of this 
regulation and identified the hydrophobic groove of the Bcl-xL as the binding 
site by which Bcl-xL binds to the channel. This was demonstrated by using a 
combination of experimental and modeling methods, including site-directed 
mutagenesis, a fluorescence quenching assay, a mitochondrial outer membrane 
  
permeability assay, and molecular dynamic simulations. Interestingly, the 
hydrophobic groove serves to inhibit another channel former, Bax. We found 
that the binding sites for Bax and ceramide on Bcl-xL are distinct but 
overlapping. We used that fact to generate mutants that have differential 
abilities to inhibit one or the other of these channels. These are useful because 
although ceramide is important in apoptosis, it is still controversial that whether 
ceramide channels result in apoptosis in vivo. To probe the relative importance 
of these two channels in apoptosis, Bcl-xL mutant proteins were expressed in 
Bcl-xL deficient cells. Weakening the inhibitory potency of Bcl-xL on either 
Bax or ceramide channels resulted in cells being more sensitive to the induction 
of apoptosis. This is the first evidence for the role of ceramide channels in the 
apoptotic process in vivo.  
In a separate investigation, a novel voltage-gated channel unit was 
found in E. coli extracts. The unit is consistent with three channels forming the 
functional triplet. These channels are highly voltage gated and highly 
cooperative. Those results indicated that one of the channels is oriented in an 
antiparallel fashion compared to the rest.  This arrangement is very rare in 
protein channels. Rectification of the current flowing through the channels was 
used to identify the orientation of the channels to provide evidence for or against 
the antiparallel hypothesis. The results favor the antiparallel hypothesis but also 
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Chapter 1: General Introduction 
1.1 Apoptosis 
Apoptosis is a type of programmed cell death and occurs during normal 
development and tissue homeostasis. It is highly regulated to exactly control 
when and where it will occur. Dysfunction of this process is fundamental to 
diseases, such as cancer, stroke, and viral infections. It also can result in 
congenital abnormalities, such as webbed toes. In this process, unwanted cells 
are removed cleanly. A cell triggers apoptotic process in response to a stress, 
such as DNA damage, aging, UV light exposure, viral infection and 
overproduction of reactive oxygen species. Cells dying by apoptosis undergo 
several morphological changes, including cells shrink and detach from its 
neighbors, the cytoskeleton collapses, the nuclear envelope disassembles, and 
chromatin condenses and breaks up into fragments (1). The cell surface 
becomes irregular and bulges outward to form membrane-enclosed vesicles, 
also as known as apoptotic bodies. The neighboring cells and macrophage 
recognize and engulf the apoptotic bodies quickly. In this way, the formation of 
apoptotic bodies prevents leakage of cellular contents and avoids inflammation 
or autoimmune reactions, which may damage surrounding tissues. In contrast, 
when cells undergo necrosis, an uncontrolled and passive cell death, which 
usually occurs due to trauma, cells swell and the plasma membrane ruptures 
(2). In this way, dead cells release the cellular contents and induce inflammatory 





understanding the molecular mechanism of apoptosis is fundamental to the 
development of diseases and finding and their cure.  
1.1.1 Extrinsic and intrinsic apoptotic pathway 
Based on the stimuli resources, such as UV light exposure, DNA 
damage, and aging, apoptosis is divided into two groups: extrinsic pathway and 
intrinsic pathway, which are triggered by the extracellular and intracellular 
signals, respectively (Fig. 1.1). In extrinsic pathway, take Fas ligand on the 
surface of killer lymphocyte for example. When it binds to death receptors in 
the plasma membrane, this binding activates the intracellular domain of the 
receptors and recruits proteins (including procaspase-8 or -10) to form death-
inducing signaling complex (DISC). Procaspase is an inactive precursor of 
cysteine-aspartic proteases (caspases). Caspase-8 and -10 then activate caspase-
3, -6, and -7, which then activate other caspases and target proteins, and results 
in the execution of apoptosis and the morphological changes, such as nuclear 
lamina breakdown, cytoskeleton collapse, and DNA fragments. In contrast, the 
intrinsic pathway is triggered by intracellular signals, such as DNA damage and 
lack of nutrients, and release intermembrane space (IMS) proteins, including 
cytochrome c, apoptosis-inducing factor (AIF), heat shock proteins, 
Smac/Diablo, and endonuclease G, to cytosol (3). It was a surprising discovery 
that mitochondria are not only as powerhouse, producing ATP via oxidation 
phosphorylation but also play a role in apoptosis. Cytochrome c, a water-soluble 





function once it is released into cytosol. It recruits apoptotic protease activating 
factor-1 (Apaf-1) and procaspase-9 to from a complex, apoptosome, and then 
result in caspase-9 activation. The caspase-9 induces the downstream caspases 
and the execution of apoptosis. These two pathways are not independent and 
are linked by a BH3-only protein, Bid. The active caspase-8 in extrinsic 
pathway cleaves the inactive form of Bid. The truncated and active form of Bid, 
t-Bid, translocates to mitochondrial outer membrane (MOM), causes the MOM 
permeabilization (MOMP), and results in the execution of apoptosis.  
Figure 1.1. Extrinsic and intrinsic pathways of apoptosis. Shown is a simplified 
schematic view of apoptotic pathways. Apoptosis may be triggered by activation of 
cell surface receptors (extrinsic pathway) or by intracellular mechanism (intrinsic 
pathway). Both pathways are able to activate caspase cascade and initiate the 
execution phase of apoptosis. Both pathways are linked by BH3-only proteins 
(Bid). Activated Bax and ceramide will cause the mitochondrial outer membrane 
permeabilization (MOMP) and activate caspase cascade. Bax and ceramide are 





Normally, the MOM only permeable to molecules less than 5 kD 
because of porin channel, but the MOM is impermeable to IMS proteins 
(cytochrome c is 12 kD). During the apoptotic process, the IMS proteins are 
released. This indicates the permeability of the MOM is changed. Several 
mechanisms may explain the MOMP, including the permeability transition (4), 
channels formed by Bax oligomers (Bax channel) (5, 6), the mitochondrial-
induced channel (MAC) (7), interactions between Bax and ceramide (8, 9), and 
ceramide channels (10, 11).  
1.1.2 Bcl-2 family proteins regulate MOMP 
Once MOMP occurs, cells do not recover because of defective function 
of mitochondria and the irreversible apoptotic process. This process is tightly 
controlled to ensure the process is triggered in the right time and the right 
location. Bcl-2 family proteins were discovered to regulate the MOMP. For 
example, Bcl-2 inhibits the release of cytochrome c and Bax and t-Bid cause 
the membrane permeabilization (12–17).  
Bcl-2 family proteins share up to four Bcl-2 homology domains (BH1-
4) (Fig. 1.2). In addition, Bcl-2 family proteins can be classified on the basis of 
the number of Bcl-2 homology domains they process and on their antiapoptotic 
or proapoptotic function (Fig 1.2). Antiapoptotic proteins are multi-domain 
proteins, including Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and A1. Proapoptotic proteins 
include multi-domain proteins (Bax and Bak) and BH3-only proteins. BH3-





heterogeneous. BH3-only proteins can be subdivided into two groups. One 
group is activator BH3-only proteins (Bid and Bim), which activate Bax or Bak. 
The other group is de-repressor/sensitizer BH3-only proteins (Puma, Bad, Bik, 
Noxa and others), which neutralized the antiapoptotic proteins.  
The Bcl-2 family proteins have been found in variety of sub-cellular 
locations in normal cells. For example, in the mitochondria, Bak resides in the 
MOM and is inhibited by VDAC2, Voltage-Dependent Anion Channel isoform 
2 or antiapoptotic proteins (Bcl-2, Bcl-xL, and Mcl-1) (18–22). In cytosol, the 
BH3-only proteins form heterodimers with and inactivate Bcl-xL or Mcl-1 (23). 
Figure 1.2. The Bcl-2 family proteins. The Bcl-2 family proteins regulates the 
MOMP. They share up to four Bcl-2 homology (BH) domains. All of them have the 
critical BH3 domain. They are divided into antiapoptotic, proapoptotic, activator 
BH3-only, and de-repressor/sensitize BH3-only subgroups. TM stands for 
transmembrane domain. Helices 1-9 of Bcl-xL are shown on the top. Bid is shown 





Bid and most of Bax are cytosolic proteins and some of Bax are loosely attached 
to the MOM (24, 25).  
To occur in the right time and right location, apoptosis is highly 
regulated by a complicated network. It is general agreed the Bax-induced 
apoptosis is regulated by the balance of antiapoptotic and proapoptotic proteins. 
Current model used to explain this balance is illustrated in Fig. 1.3 (14, 26, 27). 
BH3-only proteins serve as sensors of intrinsic apoptosis, because they respond 
to DNA damage or ER stress and translocate to MOM. For example, after 
receiving apoptotic signal, caspase-8 cleavages and activates Bid. Then t-Bid, 
the active form of Bid, translocates to the MOM. t-Bid recruits and activates 
Bax and Bax integrates into the MOM (14, 28). After that, the activated Bax in 
the membrane recruits and activates more Bax and subsequently form Bax 
channel. While Bax channel forming, IMS proteins are release because of 
MOMP at the same time. The antiapoptotic proteins are able to inactive Bax or 
activator BH3-only proteins in the cytosol or the MOM by forming heterodimer 
(23, 29–33). Moreover, the activity of antiapoptotic proteins is inhibited by the 
Figure 1.3. Current model for activation of proapoptotic protein. BH3-only 
proteins are able to activate Bax directly (activator BH3-only proteins) or indirectly 
(de-repressor/sensitizer BH3-only proteins). Bcl-xL inhibits the activity of Bax 
either directly (forming heterodimer with Bax) or indirectly (sequester the activity 





de-repressor/sensitizer BH3-only proteins. In sum, to occur MOMP, two events 
are required: all the antiapoptotic proteins are inhibited and Bax is activated. 
The interactions between Bcl-2 family proteins are primary through their 
hydrophobic groove and BH3 domain of another proteins.  
1.1.2.1 Structures of Bcl-2 family proteins and small molecules 
interrupt the potency of Bcl-xL 
The soluble structures of antiapoptotic and proapoptotic protein are 
similar. The structure of Bax channel and the apoptotic/antiapoptotic 
heterodimer in the membrane are not clear. The soluble structures of full-length 
Bax, Bcl-xL∆C (lacking of transmembrane domain and unstructural loop 
between 1 and 2), and Bcl-w∆C10 (lacking 10 residues in C-terminal) were 
solved. The structure shown in Fig. 1.4 are Bcl-xL∆C/Bim (PDB: 1PQ1), Bax 
(PDB: 1F16), and Bcl-w∆C10 (PDB 1O0L) (34–36). Structure of Bax and Bcl-
w∆C10 are composed of nine -helices (1 to 9). The 9 (the transmembrane 
helix) of Bcl-xL∆C is removed. Two hydrophobic helices (5 and 6) in the 
center form the core of the protein. Seven amphipathic helices are around these 
two central helices. Bcl-2 family proteins interact to each other through the 
hydrophobic groove. BH1, BH2, and BH3 are near to each other and form one 





The hydrophobic groove is full by the 9 (transmembrane helix) and is capable 
Figure 1.4. Structures of Bcl-2 family proteins. Ribbon representation of (A) Bcl-
xL∆C/Bim (PDB: 1PQ1). Connolly surface of (B) Bcl-xL∆C/Bim, (C) Bax (PDB: 
1F16), (D) Bcl-w∆C10 (PDB 1O0L), and (E) Bcl-xL/ABT-737(PDB 2YXJ). 
Substrates bind to the hydrophobic groove are colored in yellow (Bim peptides, the 
9 helix of Bax and Bcl-w∆C10 and ABT737). BH1, BH2, BH3, and BH4 region 







The hydrophobic groove is full by the 9 (transmembrane helix) and is capable 
to bind to the BH3 domain to form heterodimer through hydrophobic 
interactions. For example, in Bcl-xL∆C/Bak peptide complex (PDB: 1BXL), 
several hydrophobic residues of Bak peptide (V74, L78, I81, I85) make contact 
with hydrophobic residues of Bcl-xL (F97, Y101, F105, L108, V126, L130, 
V141, and F146) (37). The interactions between BH3 domain and the 
hydrophobic groove are the key aspect of apoptosis regulation. This 
hydrophobic groove is occupied by transmembrane helix. Therefore, a 
conformation change of antiapoptotic proteins is required to expose the 
hydrophobic groove and then form heterodimer with proapoptotic proteins. As 
would be expected, occupied hydrophobic groove moderate decreases the 
affinity of BH3 proteins and peptides to antiapoptotic protein (35). In addition, 
the residues in BH3 domain used to form heterodimer or homo-oligomer point 
toward the core of the proteins. This indicates another conformational change 
is required to expose the BH3 domain.  
Many cancer cells take an advantage of defects in their apoptotic 
process. The Bcl-2 antiapoptotic proteins are considered attracted targets of 
chemotherapy as their overexpress is observed in many cancer cells (38, 39). A 
small molecule, either nonpeptide or derived from BH3 domains, mimics the 
BH3-only proteins by occupying the hydrophobic groove of the antiapoptotic 
proteins, inhibiting their function and then triggering the apoptosis. For 
example, Antimycin A3, 2-methoxy antimycin A3, ABT-737, and ABT-263 are 





BID BH3 (40, 41). ABT-737 selective inhibits three antiapoptotic proteins (Bcl-
xL, Bcl-2, and Bcl-w) but not Mcl-1 and A1. Its oral derivative, ABT-263, 
shows promising data of phase I/II clinical trials for various cancer cells (42–
46). The crystal structure of Bcl-xL/ABT-737 shows that ABT-737 binds to a 
part of the hydrophobic groove that is close the BH123 end of the hydrophobic 
groove.    
The membrane structure of Bcl-2 family proteins are still unclear and 
under investigation. The majority of Bax is in cytosol and small portion of Bax 
is loosely attached to mitochondria, as it can be extracted by sodium carbonate 
(47). After apoptotic stimuli, Bax is constitutively inserted into the MOM (48, 
49), presumably via its transmembrane helix (9). When Bax is activated, it 
undergoes a conformational change, inserts its 5 and 6 into the MOM and 
then exposes its BH3 domain (48, 50–54). Consequently, Bax channels form 
and result in the MOMP.  
1.1.3 Ceramide role in mitochondrial mediated apoptosis 
Ceramide, a sphingolipid, is composed of a sphingoid base (18 carbons) 
and an acyl chain (14 to 16 carbons) linked via an amide bond at C2 of the 
sphingoid base (Fig 1.5). The sphingoid base consists of two hydroxyl groups 
at C1 and C3, a trans double bound across C4 and C5, and an amine on C2. 
Ceramide is involved in several cell processes, such as cell differentiation, cell 






1.1.3.1 Cellular ceramide is important in apoptosis 
Several cellular observations indicate that ceramide plays an important 
role in apoptosis. First, in various cell types, ceramide generation is a common 
response to apoptotic reagents, such as TNF, interleukin-1, or –interferon 
(55–60). Second, the effective dose of these apoptotic reagents required to 
induce ceramide generation and apoptosis are closely matched (61). Third, 
apoptotic reagents induce the elevation of cellular ceramide before the 
execution phase of the apoptotic process (55, 62, 63). Fourth, ceramide-induced 
apoptosis is specific. For example, dihydroceramide, a ceramide precursor, 
does not induce apoptosis (60, 64). Fifth, elevation of cellular ceramide induces 
apoptosis in various cell types. Elevation of ceramide can be done via addition 
of apoptotic agents, exogenous membrane-permeable ceramide analogues, or 
inhibitors of ceramide metabolism (55, 60, 65–69). These indicate ceramide is 
important in apoptotic induction. 
 






1.1.3.2 Mitochondrial ceramide is important in apoptosis 
Regulation of ceramide generation in mitochondria is important in 
apoptosis. Failure in this regulation contributes the immortality of cancer cells. 
In general, the level of ceramide is kept in low (70). When cells receive 
proapoptotic signals, the level of ceramide in the mitochondria increases (55, 
58, 71). For example, UV irradiation resulted in an increase in mitochondrial 
ceramide and the release of cytochrome c in HeLa cells (71). Inhibition of 
sphingolipid metabolism prevents ceramide synthesis and also prevents the 
onset of apoptosis. In addition, Birbes et al. expressed the bacterial 
sphingomyelinase (bSMase), which converts sphingomyelin to phosphocholine 
and ceramide, in different organelles in MCF7 breast cancer cells (72). Only 
when bSMase was targeted to mitochondria and increased the level of 
mitochondrial ceramide, was cytochrome c released from mitochondria and the 
cells underwent apoptosis. Therefore, the level of mitochondrial ceramide is 
critical for ceramide-induced apoptosis. Although most sphingolipid 
metabolism occurs at locations outside of mitochondria, such as the 
endoplasmic reticulum (ER), the Golgi apparatus, and the plasma membrane, 
ceramide produced distally can be rapidly transferred to mitochondria. 
Specialized ER associated with mitochondria, known as mitochondrial 
associated membranes, can rapidly transfer its ceramide to mitochondria (73). 
In addition, mitochondria are also able to generate ceramide because they 
processe ceramide synthase and ceramidase (74–76). This also indicates that 





1.1.3.3 The existence of ceramide channels in the MOM 
Early studies indicated that elevation of mitochondrial ceramide induces 
the release of IMS proteins and induces apoptosis (55, 58, 71). The release of 
IMS proteins indicates that the outer membrane of mitochondria becomes 
permeable. Whereas the sphingolipid community is focused on ceramide acting 
on proteins to alter cellular function, ceramide was also shown to form large 
stable channels in membranes (10, 77–79). The proposal that hundreds of 
ceramide molecules would self-assemble into a large lipid channel is very novel 
and not generally accepted. However, the experimental evidence for channel 
formation is very strong. First, ceramide does not cause the release of the 
mitochondrial matrix enzyme, fumarase, while it causes the release of IMS 
proteins such as cytochrome c (11). This indicates a specific permeabilization 
of the MOM. Second, ceramide did not permeabilize the plasma membrane of 
erythrocytes or destroy the solvent-free planar phospholipid membranes (10, 
77), further indicating that the ceramide-induced permeabilization is not merely 
a non-specific, detergent-like effect. Indeed, this indicates that ceramide 
selectively permeabilizes the MOM but not the mitochondrial inner membrane 
(MIM) or the plasma membrane. In addition, bovine serum albumin (BSA) and 
an antiapoptotic protein, Bcl-xL, are able to reverse the MOMP and restore the 
permeable barrier of the MOM (17, 77). This indicates that ceramide channels 
are in dynamic equilibrium with ceramide monomers in the membrane and BSA 
shifts the equilibrium away from ceramide channels in the MOM to the 





of the ceramide channel is sensitive to the concentration of ceramide present or 
added again indicating a dynamic equilibrium. Under certain conditions 
ceramide allows the release of IMS proteins below 60 kD from mitochondria 
(10, 11), but larger channels are formed under other conditions (78).  
In 2000, Siskind and Colombini reported the formation of ceramide 
channels in planar phospholipid membranes and later in the MOM (10, 11). 
Channel formation is not only supported by the observation of discrete 
increments of conductance in the planar phospholipid membrane, but also the 
ceramide channels observed in liposomes under the electron microscope (78). 
They vary in size but have an average size of ten nanometers in diameter (10, 
78). Ceramide channels form at physiological mole fractions in the MOM (77). 
The level of ceramide required for channel formation in the MOM of isolated 
mammalian mitochondria is a little less than the level of ceramide present in 
the MOM during the induction phase of the apoptotic process that is before or 
at the time of cytochrome c release (77). This suggests ceramide forms channels 






1.1.3.4 Structure of ceramide channels 
A model of the ceramide channel is illustrated in Fig 1.6 (79–81). The 
channel is doughnut-shaped forming a 10-nanometer diameter pore. This is the 
typical size determined experimentally. This model consists of 48 ceramide 
columns. Each ceramide column is composed of six ceramide molecules, the 
length of which is sufficient to span the hydrophobic part of the membrane. The 
Figure 1.6. Model of the ceramide channel. A. A model of a ceramide channel as 
it would exist on a membrane. This is composed of 48 ceramide columns arranged 
in an antiparallel orientation. The red atoms forming the inner lining of the pore are 
oxygens. The number of columns varies forming channels of different pore 
diameter. The illustrated structure forms a 10 nm diameter pore and this is the 
typical size detected by electrophysiological recordings and electron microscopy.  
The crystal structure of Bcl-xL is superimposed on one portion of the channel, 
sitting over the apolar tails of the ceramide molecule at the end of one of the 
columns. B. A pair of ceramide columns in an anti-parallel orientation. Each 
column consists of 6 ceramide molecules connected by a network of hydrogen 
bonds (yellow). The amide linkage in the ceramide molecule is believed to be 
responsible for the major intermolecular hydrogen bond that connects the ceramide 
molecules. The twin hydroxyls and the bridging water molecules also form part of 





inner surface of the channel is composed of the hydrophilic head of the 
ceramide molecules and the two hydroxyl groups form a hydrogen bonded 
network with water molecules in the channels. In contrast, the hydrophobic tails 
embed into the phospholipid bilayer. The six ceramide molecules are held 
together by intermolecular hydrogen bonding. The carbonyl oxygen of a 
ceramide molecule forms a hydrogen bond with the amide hydrogen of its 
adjacent ceramide. This interaction is similar to that of the alpha helix in 
proteins. This hydrogen bonding between ceramide molecules forms a dipole 
moment. The alignment of these dipoles parallel to the axis of the column 
causes a net dipole moment from the free carbonyl at one end of the column to 
the free amide at the other end. The columns are organized in antiparallel 
fashion to achieve favorable dipole-dipole interactions between columns. In 
addition, each ceramide molecule forms C1-C1 and C3-C3 hydroxyl-hydroxyl 
interactions with adjacent ceramide molecules linking the columns together.  
 Molecular dynamic (MD) stimulations provide support for the stability 
of this structure (80). These also reveal how the structural properties of the 
ceramide molecule affect the channel’s shape. In general, the local curvature of 
a lipid is due to the size ratio of the head group of the lipid to its hydrophobic 
region. If the ratio is close to one, the curvature will be zero and the lipid will 
form a planar membrane. If the ratio is bigger than 1, the lipid will generate a 
positive curvature. If the ratio is smaller than 1, the lipid generates a negative. 
From the MD simulations, the ceramide molecule in the channel takes the shape 





the two arms. Therefore, the curvature is negative and positive in the plane of 
the membrane and along the axis of the channel, respectively. This forms a 
doughnut-shaped channel and an hourglass conductive pathway. As the channel 
is embedded in the phospholipid membrane, the phospholipids cover the acyl 
chains of the ceramides at the end of the channel to avoid unfavorable high-
energy exposure to the aqueous solution. The interfacial phospholipids curve 
toward the channel and the ceramides curve toward the phospholipids thus 
forming a continuous polar surface interfacing with the water phase. 
1.1.3.5 Regulation of ceramide channels 
Factors involved in the apoptotic process are tightly regulated. 
Therefore, the formation of ceramide channels in the MOM must be tightly 
regulated in several ways (82). First, cell regulates the formation of ceramide 
channels by controlling the ceramide level in the MOM. The formation of 
ceramide channels is sensitive to the ceramide level in the MOM (77). Cells 
keep the level of mitochondrial ceramide low. The level only increases in the 
MOM after the apoptotic signal is delivered (58, 83, 84). The steady level of 
mitochondrial ceramide would be affected by the activity of mitochondrial 
enzymes involved in the de novo pathway (ceramide synthase) or hydrolysis 
pathway (ceramidase) (75, 76). Indeed, cells overexpressing sphingomyelinase 
targeted to mitochondria undergo apoptosis and release of cytochrome c (83). 
In addition, the cell regulates the formation of ceramide channels through the 
Bcl-2 family proteins. Antiapoptotic proteins, Bcl-xL, Bcl-2 and CDE-9 (the 





ceramide-induced MOMP in isolated rat mitochondria (17). In contrast, Bax, a 
proapoptotic protein, was found to increase MOMP with ceramide 
synergistically (85).  
Although antiapoptotic proteins inhibit ceramide-induced MOMP, it is 
unclear whether the antiapoptotic proteins interfere with the MOMP directly or 
indirectly. The antiapoptotic proteins may reduce the MOMP by binding to the 
endogenous apoptotic proteins, such as BAK, in isolated rat mitochondria. 
However, the ability of Bcl-xL to reduce MOMP was also observed in 
mitochondria isolated form yeast, which lacks Bcl-2 family proteins (17). 
Therefore, in this case the reduction of MOMP by Bcl-xL is not due to the 
neutralization of other proapoptotic proteins known to bind to Bcl-xL. This 
result cannot eliminate the possibility that Bcl-xL may interact with other 
components in the isolated mitochondria and interfere with MOMP. However, 
Bcl-xL is able to disassemble ceramide channels in pure 
phospholipid/cholesterol membranes (17). This indicates that Bcl-xL regulates 
the ceramide channels in the MOM directly. Moreover, the Hill coefficient of 
Bcl-xL preventing the MOMP is 1 (17). This suggests that Bcl-xL regulates the 
ceramide channel in an uncooperative manner and a ceramide channel is 
disassembled by a single monomeric Bcl-xL.  
Both activated Bax and ceramide are each able to cause the 
permeabilization of the MOM or a phospholipid membrane. However, 
combinations of Bax and ceramide increase MOMP to a much higher level than 





(85). This suggests that activated Bax stabilizes the structure of ceramide 
channels or somehow these act synergistically. 
1.1.3.6 Studies of the molecular mechanism by which Bcl-2 family 
proteins regulate ceramide channels  
So far ceramide and its analogs are unique in their ability to form large 
stable lipid channels. Thus it is not surprising to learn that the regulation of lipid 
channels by proteins is a new field. Ceramide analogs were used to probe the 
how the ability of Bcl-xL to inhibit ceramide channels is influenced by the 
molecular structure of ceramide. The analogs studies indicate that Bcl-xL 
interacts with the acyl chain of ceramide (81). Bcl-xL optimally inhibits 
channels formed by intermediated chain-length ceramide, such as C16- and 
C18- ceramide. The ability of Bcl-xL to inhibit channel formation declines 
obviously when the length of the acyl chain is longer or shorter than that of C16 
or C18 ceramide. In addition, small chemicals (ABT-737, ABT-263, and 2-
methoxyantimycin A3), known to bind to the hydrophobic groove of Bcl-xL, 
interfere with the ability of Bcl-xL to inhibit ceramide-induced MOMP. These 
results suggest that Bcl-xL regulates the ceramide channels through binding of 
the hydrophobic tails of ceramide by its hydrophobic groove. Furthermore Bcl-
xL needs to be bound to a membrane, because truncated Bcl-xL, lacking its 
transmembrane domain, is unable to reduce the ceramide-induced MOMP (17). 
Using this information, the structural model of the channel and a 1:1 interaction 
between Bcl-xL and the channel, Perera and Colombini proposed a molecular 





MOM (81). Bcl-xL displaces the phospholipids covering the acyl chains of 
ceramide at the end of one of the columns. This displacement removes the 
influence of the phospholipids on that ceramide column causing it to relax into 
a form with less curvature. This column will be mismatched relative to the acyl 
chains of the adjacent columns resulting in a conformational stress that 
propagates throughout the structure through the hydrogen-bonded network. 
This is equivalent to the conformational propagation in an allosteric interaction. 
This stress destabilizes the channel structure and results in channel disassembly 
because the channel is in dynamic equilibrium with ceramide monomers and 
non-channel-forming aggregates. 
1.2 Voltage-gated channels 
Voltage-gated channels are transmembrane proteins whose 
permeability is dependent on the membrane electrical potential. While the 
channel is opened, water-soluble molecules or ions can passively cross the 
membrane down their electrochemical potential gradient. A change in the 
membrane potential results in a change in the probability of a typically charged 
voltage sensor domain (VSD) within the channel to move through the electric 
field resulting in a conformational change. This conformational change is the 
opening or closure of the channel. These channels have evolved to both control 
and respond to changes in the membrane potential. Most voltage-gated channels 
are found in the plasma membrane of excitable cells, such as neurons and 
muscles (86, 87). Voltage-gated sodium/potassium/calcium channels are 





propagation of action potentials and the secretion of hormones and 
neurotransmitters. Voltage-gated channels are also found in other types of 
membranes and cells, such as bacteria (88) and viruses (89), and intracellular 
organelles (90). For example, voltage-gated calcium channels allow 
Paramecium to regulate swimming direction and circumvent obstacles (91). 
VDAC channels, abundant proteins in the MOM, regulate the flux of 
metabolites across the MOM. However, the role of voltage-gated channels in 





Chapter 2: Materials and Methods 
2.1 Purification of recombinant proteins 
2.1.1 Construct Bcl-xL mutants 
A full-length construct of human Bcl-xL in the pGEX2T vector 
(Amersham Pharmacia Biotech), which includes ampicillin-resistance, was a 
gift from Dr. Marie Hardwick. All single mutations of Bcl-xL were introduced 
using the QuickChange Site-Directed Mutagenesis procedure (Stratagene) 
outlined below unless noted. PCR was performed with 0.5 M primers, 0.2 mM 
dNTPs, 1 ng/l Bcl-xL/pGEX2T, and 50 mU/l U PfuUltra (Agilent 
Technologies). Each PCR product was treated with 0.4 U/l DpnI (New 
England BioLabs) at 37oC for 1 hour. 5 l of aliquot was transformed into Z-
competent cells (Zymo Research) and then the cells were plated on LB with 
100 g/ml ampicillin, incubated at 37 oC overnight. A single colony was 
inoculated into 10 ml LB medium with 100 g/ml ampicillin and incubated at 
37 oC overnight. Each construct was isolated with GeneJet Plasmid Mimprep 
Kit (Thermo Fisher Scientific) and verified by DNA sequencing. 
2.1.2 Purification of human full-length Bcl-xL and its mutants 
The expression and purification of full-length Bcl-xL were previously 
described (93) and modified (81). In brief, a glutathione S-transferase (GST) 
tag was fused to the N-terminal of human full-length Bcl-xL with a thrombin 





a bacterial system and then isolated by using glutathione-agarose beads, which 
bind the GST tag. Adding biotinylated thrombin to the GST column results in 
the release of full-length Bcl-xL, while the GST tag remained in the GST 
column. The biotinylated thrombin was removed by using streptavidin beads.  
The construct of Bcl-xL and its mutants was transformed into BL21 
(DE3) pLysS competent cells and plated on LB/agar plates with 100 g/ml 
ampicillin, following the E. coli Competent Cells: Multiple-Use protocol from 
Promega. One colony was inoculated into 50 ml seed culture and shaken at 37 
oC overnight. The seed culture was inoculated into 1L LB with 100 g/ml 
ampicillin and shaken at 37 oC until OD reached around 0.6. Then 10 M 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added and shaking 
Table 1 Primers used to produce Bcl-xL mutants (codon and base mutated are 
underlined and bold, respectively) 
 
Mutant  Primer sequence 5’ to 3’ 
E96L Forward GGGAGGCAGGCGACCTGTTTGAACTGCGGT 
E96L Reverse ACCGCAGTTCAAACAGGTCGCCTGCCTCCC 
F97Q Forward GAGGCAGGCGACGAGCAGGAACTGCGGTACCGG 
F97Q Reverse CCGGTACCGCAGTTCCTGCTCGTCGCCTGCCTC 
F100L Forward CGAGTTTGAACTGCTGTACCGGCGGGCAT 
F100L Reverse ATGCCCGCCGGTACAGCAGTTCAAACTCG 
F105Q Forward GCGGTACCGGCGGGCACAGAGTGACCTGACATC 









F146A Forward GTGGCCTTTTTCTCCGCCGGCGGGGCACTGTGC 










continued for two hours. Cells from 4 L of culture were harvested by spinning 
at 5,000 g at 4 oC for 20 minutes (JS-4.2 rotor) and then were resuspended into 
30 ml phosphate buffered saline (PBS) with 1% Triton-X100 and 36 M 
phenylmethylsulfonyl fluoride (PMSF). The resuspended cells were stored at -
20 oC.  
To isolate the Bcl-xL and its mutants, the cells were thawed and shaking 
with 167 U/ml lysozyme resumed at 4 oC for 20 minutes.  Cells were lysed by 
three passages through a French Press using 1,000 Psi. The following steps were 
performed at 4 oC. The lysate was spun at 100,000 g for 30 minutes by 50Ti 
rotor to remove cell fragments and debris. The supernatant was filtered through 
a 0.2 m filter to remove particles that may clog the column. Then the 
supernatant was gently shaken with 5 ml glutathione agarose beads (Thermo 
Fisher Scientific), which were pre-equilibrated with PBS buffer, for two hours. 
The beads were packed into a column, washed with at least 10 column volumes 
(50 mL) of PBS buffer with 36 M PMSF and then at least 10 column volumes 
(50 mL) of 20 mM Tris-HCl, pH8. After the washing process, the beads were 
gently shaken with 10 ml of 20 mM Tris-HCl, pH 8.0 containing 5 U of 
biotinylated thrombin overnight. The beads were packed into a column, the flow 
through was collected, and 1.5 ml of 20 mM Tris-HCl, pH 8.0 was added to 
replace the void volume of the column. The biotinylated thrombin in the aliquot 
was removed by gently shaking with 80 l streptavidin beads (Thermo Fisher 
Scientific), pre-equilibrated with 20 mM Tris-HCl, pH 8.0, for 30 min. The 





with 10 %, v/v glycerol was passed through 0.2 m filter. Then 100 l aliquots 
of the final product were rapidly shell-frozen in an ethanol-dry ice bath and 
were stored in -80 oC. BCA assay was used to determine the concentration of 
Bcl-xL and its mutants.  
2.1.3 Purification of human Bax 
The purification of human Bax was previous described (34) and 
modified (85, 94). In brief, the construct of human Bax/pTYB1, a gift from Dr. 
Richard Youle, expressed human Bax with a C-terminal intein tag. The intein 
tag allows the fusion protein to bind to chitin beads and the tag can be removed 
by addition of DTT (dithiothreitol). This results in a one column purification of 
human Bax.  
The construct was transferred into BL21 (DE3) pLysS competent cells 
and plated on LB/agar plates with 100 g/ml of ampicillin. A few colonies were 
inoculated into 40 ml of Terrific Broth medium and shaken at 37 oC until the 
OD reached 0.6 – 0.8. The culture was inoculated into 2 L of Terrific Broth 
medium (1 L medium in 2 L flask). When the OD reached 0.6, the cell culture 
was shaking with 1 mM IPTG for 3 hours. Then the cells were sedimented by 
spinning at 5,000 g (JS-4.2 rotor) at 4 oC for 20 min and resuspended in 
resuspension buffer (20 mM Tris-HCl, pH 8.0, 5 mM EDTA, and 500 mM 
NaCl). The resuspended cells were stored in -20 oC.  
The procedure for cell lysis was the same as that described for the 
purification of human Bcl-xL except that no detergent, protease inhibitors, and 





soluble proteins were obtained by centrifugation. The soluble proteins were 
then applied to a 3 ml chitin column ((New England BioLabs), at 4 oC, which 
was pre-equilibrated with TEN buffer (20 mM Tris-HCL, pH 8.0, 1 mM EDTA, 
and 500 mM NaCl). The chitin column was washed with 20 column volumes 
to remove unbound proteins. The column was flushed with 3 column volumes 
of TEN buffer with 30 mM DTT and was incubated at 4 oC for 48 hours to 
release the Bax. Bax was eluted by addition of 3 column volumes of TEN 
buffer. To remove the NaCl, EDTA, and DTT, Bax was dialyzed with 6,000 – 
8,000 MW cut-off dialysis membrane against 3 L of 10 mM Tris-HCl, pH 8.0, 
1 mM EDTA overnight followed by 5 L of 10 mM Tris-HCl, pH 8.0 overnight. 
After addition of glycerol (final concentration, 10 %, v/v), 100 l aliquots of 
final product were shell-frozen in ethanol-dry ice bath and were stored in -80 
oC. The protein concentration was determined by the BCA assay.  
2.1.4 Purification of t-Bid 
Full length Bid was engineered into pGEX4T1 vector. A GST tag was 
added to the N-terminal of Bid with a thrombin cleavage site between the tag 
and Bid. However, when cells undergo apoptosis, Bid is cleaved by caspase-8 
to yield the C-terminal active fragment. This is known as truncated Bid (t-Bid). 
Therefore, a thrombin cleavage site was introduced to mimic the caspase-8 
cleavage site. In this way, one is able to obtain both fragments of Bid with one 






The purification was previously described (15, 95) and modified (85). 
In brief, the construct of full length of Bid was transformed into BL21 (DE3) 
pLysS and inoculated into 100 ml LB medium with ampicillin. When the OD 
reached 0.6, 0.4 mM IPTG was added and shaking resumed for 3 hours at 37 
oC. The cells were spun and resuspended in PBS buffer with 1 mM EDTA, and 
500 mM NaCl. Then 5 l lysozyme was added and shaking at 4 oC for 30 
minutes. After 3 passages through the French Press to lyse the cells, Triton-
X100 was added (final concentration was 0.1 %) and shaking resumed at 4 oC 
for 15 more minutes. After spinning, the supernatant was filtered and shaking 
with 1 ml GST agarose beads at 4 oC overnight. The beads were spun at 500 g 
for 5 minutes at 4 oC, washed with 50 ml PBS buffer, and spun again. The beads 
were transferred to a column and washed with 10 ml PBS. The beads were 
resuspended in 0.5 ml PBS and were shaken with 10 U biotinylated thrombin 
at 4 oC overnight. The next morning, 3.5 ml of protein was collected and the 
thrombin was removed by using 70 l of streptavidin beads. The supernatant 
was transferred to an 8,000 D MW cut-off dialysis bag and dialyzed against 5 
L 50 mM Tris-HCl, pH 8.0 at 4 oC overnight. The concentration of the final 
product was determined by the BCA assay, and aliquots were shell-frozen in 
ethanol and dry ice bath, and stored at -80 oC. 
2.2 Binding of ceramide to Bcl-xL 
Because ceramide is insoluble in water, in an aqueous environment once 
bound it is unlikely to dissociate. Therefore an equilibrium binding experiment 





specific binding. In brief, fluorescently-labeled ceramide was dispersed into a 
solution containing Bcl-xL. Since ceramide is insoluble, ceramide not bound to 
Bcl-xL forms micelles. The density of the micelles is less than that of the 
aqueous solution and this difference was increased by using sucrose. Therefore, 
the fluorescent ceramide micelles were removed by centrifugation. The 
fluorescence of the subphase was recorded. The details of the assay are 
described below.  
The excitation and emission wavelength of fluorescently-labeled 
ceramide (C11 TopFluor ceramide; Avanti Polar Lipids) in isopropanol is 490 
nm and 504 nm, respectively. The fluorescently-labeled ceramide was stored at 
-20 oC. Before the binding assay, the concentration of fluorescently-labeled 
ceramide was determined by the standard curve (Em504 = 2.63 x 10
6 C+ 3.07 x 
104) and the concentration of wild type Bcl-xL and its mutants was adjusted to 
1.8 µM with 20 mM Tris-HCl, pH 8.0 (650 µl per sample). Nine microliters of 
42 µg/ml fluorescently-labeled ceramide were dispersed to 590 µl containing 
1.8 µM Bcl-xL wild-type or its mutants in 20 mM Tris, pH 7.4, 10% sucrose. 
The dispersal was performed by slow delivery of the ceramide solution into the 
protein solution while it was being vortexed (around 25 seconds). Entrainment 
of air was carefully avoided. In order to remove ceramide micelles, 50 µl of 20 
mM Tris, pH 7.4, 5% sucrose was applied to the top of the mixture to produce 
a density gradient. Then the gradient was spun in MLA-130 at 55,000 rpm 
(around 140,000 g) at 25oC for 30 min. 50 l of the upper layer containing 





a gel loading tip to avoid contamination of ceramide micelles. The subphase 
was excited by 490 nm incident light and the emission spectrum from 495 to 
520 nm was recorded in a FluoroMax-4. The fluorescence was not detected in 
the non-protein controls, so all fluorescence was due to ceramide associated 
with protein. The fluorescent quantum yield of the bound ceramide was varied 
depending on the protein used. Thus, in order to assess the amount of ceramide 
bound, a portion of the fluorescent solution was mixed with the same volume 
of isopropanol (to denature the protein and extract the ceramide) and spun at 
18,000 g at 4ºC for 40 min. The emission spectrum of the supernatant was 
recorded. 
2.3 Detection of mitochondrial outer membrane permeability 
2.3.1 Isolation of rat liver mitochondria 
Mitochondria were isolated from the liver of male Sprague Dawley rats 
as described originally (96) and as modified (81). A rat was fasted with water 
ad labitum overnight. All buffers needed were promptly thawed and keep on 
the ice. It is important that all the containers were pre-rinsed with buffer used 
and kept at ice cold to ensure the quality and integrity of purified mitochondria. 
1.5 g fatty-acid depleted BSA was gently scattered on the top of 300 ml H buffer 
(5 mM HEPES, pH 7.5, 0.1 mM EGTA, 210 mM Mannitol, and 70 mM 
Sucrose) and waited until the BSA dissolved without stirring. Once BSA has 





The rat was anesthetized with carbon dioxide and sacrificed by 
decapitation using a guillotine. The liver was excised and soaked in 100 ml H 
buffer with 0.5 % BSA (HB buffer). To remove the blood in the liver, the liver 
was chopped with scissors into small pieces and washed with H buffer with 0.5 
% BSA. The liver was homogenized with H buffer with 0.5 % BSA by two 
passes of a motorized Potter-Thomas Teflon-glass homogenizer. The 
mitochondria were then isolated by differential centrifugation and all the 
following steps were performed at 4 oC. The homogenate was split into four 
centrifuge tubes and filled up with HB buffer. The tubes were spun at low speed 
(2,250 rpm in an SS-34 rotor; 605 g) for 10 minutes. The supernatant was 
transfer to a new tube and spun at high speed (8,750 rpm in an SS-34 rotor; 
9,150 g) for 10 minutes. The supernatant was discarded. The fat and other 
contaminants attached on the walls of the tubes were wiped out by a Kimwipe. 
A Pasteur pipette without the capillary tip was used to gently resuspend the 
pellet with a small amount of HB buffer. Red blood cells and lysosomes might 
be left in the center of the pellet. The pellet was gently and carefully 
resuspended without disturbing any blood cells and lysosomes. The suspensions 
were combined to two centrifuge tubes. Then these two tubes were spun at low 
speed and the supernatant was transferred to new tubes. The supernatant was 
spun at high speed and the pellet was gently resuspended into small amount of 
H buffer using a blunted Pasture pipette. The isolated mitochondria were kept 
on ice. The animal use protocols were approved by the Institutional Animal 





consistent with the Panel on Euthanasia of the AVMA (American Veterinary 
Medical Association).  The animal facility used to house the animals is 
accredited by AAALAC (Association for Assessment and Accreditation of 
Laboratory Animal Care). 
The concentration of mitochondrial protein was measured as previously 
describe (97). 500 ml of 1/20 dilution of the isolated mitochondria was mixed 
with 500 ml of P buffer (100 mM Tris-H2SO4, 0.4 % SDS, pH 8.0) and the 




. Typically the concentration was 5 - 12 mg/ml. 
2.3.2 Cytochrome c accessibility assay  
The cytochrome c oxidation assay is used to monitor the permeability 
of isolated mitochondria to proteins. Reduced cytochrome c is added to isolated 
mitochondria. If it could cross the outer membrane, it would be oxidized by the 
cytochrome c oxidase on the inner membrane. If the mitochondria are intact, 
the oxidation rate is minimal. If the outer membrane is damaged, the oxidation 
rate is the maximum. After ceramide channel formation, the oxidation rate is 
somewhere between the maximum and background (17, 81). This indicates the 
rate of the cytochrome c crossing the MOM is the rate-limiting step. The initial 
rate of oxidation is a measure of the permeability of the MOM. It is also an 
indication of the size and the number of ceramide channels that formed.  
Before performing the assay, reduced cytochrome c needs to be 





0.2 M Tris-HCl, pH7.5 (J buffer) and then excess of ascorbate was added (final 
concentration, 97 mM). The reduced cytochrome c and ascorbate was separated 
by Sephadex G-10 gel-filtration column, which was pre-equilibrated with J 
buffer. After the mixture was loaded into the column, the column was wash 
with J buffer and the flow rate was 0.5 mL per minute. Because reduced 
cytochrome c is red, the red fraction was collected. The concentration of 
reduced cytochrome c was determined by spectrophotometry (550 = 18.5 mM
-
1cm-1) (98). Then the concentration was adjusted to 1.5 mM with J buffer and 
aliquotted. To prevent oxidation, the aliquots were flushed with argon, wrapped 
with Parafilm, and store at -20 oC.  
The cytochrome c accessibility assay is performed as described (99) and 
modified (11, 17, 81). Mitochondria were isolated and used on the same day.  
They were kept on ice at high concentration and diluted prior to use. For each 
run (around 18 reactions), dilutions were freshly prepared. They were 1.0 ml of 
0.25 mg/ml mitochondria in FH buffer (280 mM mannitol, 0.1 mM EGTA, 5 
mM HEPES, pH 7.4). They were kept on ice. Typically, 50 µl of 0.25 mg/ml 
mitochondria was resuspended 650 ml of room temperature H* buffer (160 mM 
mannitol, 60 mM KCl, 0.1 mM EGTA, 5 mM HEPES, pH 7.25, 1.3 M 
antimycin A, and 500 mM dinitrophenol). Then 50 μl of Bcl-xL was mixed into 
the suspension. After 5 minutes incubation at room temperate, 10 l of 1 mg/ml 
ceramide (dissolved in isopropanol) was dispersed. The dispersal was 
performed by slow delivery of the ceramide solution into the protein solution, 





carefully avoided. 15 l of reduced cytochrome c was added to the mixture. The 
sample was immediately inverted three times to mix and the absorbance at 550 
nm was recorded. Because the sensitivity of the mitochondria to ceramide might 
be variable, the concentration of mitochondria (0.25 – 0.5 mg/ml), the amount 
of ceramide (5 l – 20 l of 1.0 mg/ml), and the concentration of Bcl-xL (10 
nM – 100 mM) used needed to be adjusted in the beginning of the assay.  
2.3.3 Release of adenylate kinase 
The adenylate kinase assay measures the release adenylate kinase, 24 
kDa protein, from the intermembrane space of mitochondria and determines the 
percentage of permeable mitochondria. The assay is a coupled-enzyme assay. 
In brief, ADP is converted to ATP by adenylate kinase. Then hexokinase 
converts ATP and glucose to ADP and glucose-6-phosphate, which is 
eliminated by glucose-6-phosphate dehydrogenase and produces NADPH. All 
reaction components are in excess, except adenylate kinase. Therefore, this 
allows one to determine the amount of adenylate kinase released.  
The adenylate kinase assay was performed as previously described 
(100) and modified (11). Typically 24 adenylate kinase assays of Bax working 
solution (5 ml) were prepared. The Bax working solution was 15 nM Bax and 
36 nM t-Bid in high salt FH buffer (5 mM HEPES, pH 7.4, 0.1 mM EGTA and 
150 mM KCl). The Bax working solution was incubated at room temperature 
for 10 minutes to active Bax. Then 5 l of Bcl-xL at the desired concentration 





a mitochondria working stock of mitochondria (10 ml of 160 g/ml 
mitochondria with FH buffer (280 mM mannitol, 0.1 mM EGTA, 5 mM 
HEPES, pH 7.4). To form Bax channels, 300 l of the mitochondria working 
stock was mixed with the protein mixture and incubated at 37 oC water bath for 
30 minutes (60 mM KCl final). The mitochondria were sedimented at 14,000 g 
for 5 minutes at 4 oC and kept on ice. The supernatant containing the released 
adenylate kinase was kept on ice.  
Because the ADP containing a little bit of ATP, 6 l of 5 units of 
hexokinase and 5 units of glucose-6-phosphate dehydrogenase were incubated 
with 350 l AK buffer (5 mM MgSO4, 10 mM glucose, 5 mM ADP, 0.2 mM 
NADP, 50 mM Tris-HCl, pH 7.5) for 3 minutes prior to the assay to cover the 
remaining ATP to ADP. After the incubation, 150 l of supernatant containing 
the release of adenylate kinase was added and absorbance of 340 nm was 
immediately recorded for 5 minutes. The initial slope of increase in absorbance 
was used as a measure of the amount of released adenylate kinase.   
2.3.4 Statistics for all studies except the whole-cell experiments 
The results are reported as the mean ± S.E. (standard error) of at least 3 
independent experiments. Significance was determined by using the Student’s 
t-test. Single, double, triple and quadruple symbols, indicate significance with 





2.4 Molecular dynamic simulations 
The structure of full-length Bcl-xL-ceramide assembly was based on the 
published model from molecular dynamic (MD) studies (81) that were 
performed using the crystallographic structure of the Bcl-xL/Bim fragment 
complex (PDB ID: 1PQ1). In the experimental setting, the N-terminal part of 
Bcl-xL is preceded by a few extra amino acids (GSPRRS) inherited after 
thrombin cleavage. To better match with the experiments, we attached this 
fragment to N-terminus of Bcl-xL (however being so remote from the ceramide 
binding site, this modification should not have any significant effect). 
Fragments of Bcl-xL, unresolved in the crystal structure (residues 29 to 77) as 
well as the added N-terminal fragment were modeled using Robetta (101). N- 
and C-termini of the final Bcl-xL structure were modeled in the dissociated 
state.  
The complete system (96080 atoms) contained 3686 protein atoms (239 
residues), 106 atoms of C16-ceramide (one residue), and 2392 atoms of 
D-mannitol (92 residues – matching 160 mM mannitol in the experimental 
medium). To maintain the electroneutrality of the system K+ and Cl- ions were 
added up to an equivalent of 60 mM salt concentration, 43 K+ and 34 Cl-. 
Assembly of the simulation system, introduction of the single mutations into 
the Bcl-xL structure (see chapter 3), analysis of the results and visualization 
were performed in VMD v1.9 (102) using custom-written Tcl scripts. 
MD stimulations were done using the NAMD package (103). All the 





field (104) and TIP3P water model (105). Parameters for ceramide were taken 
from the previously published simulations (80). The acidic and basic residues 
of Bcl-xL were set in their default protonation state at pH 7.0 (estimated using 
PROPKA for neutral pH (106)). Langevin Dynamics (107, 108) was used to 
maintain constant pressure (1 atm) and constant temperature (295.15 oK). 
Periodic boundary conditions were maintained and the particle mesh used the 
Ewald method (109) with a real space cutoff distance of 1.2 nm and a grid width 
of 0.1 nm. Energy Minimization steps were performed using the steepest 
descent in the first 2000 steps and then a conjugate gradient in the subsequent 
2000 steps. To attain the equilibrium, the system was subjected to gradual 
heating until it reached to 295.15 oK (22 oC), first with the protein backbone 
harmonically restrained (100 kcal/mol/nm2 per backbone atom) to the initial 
coordinates for 1 ns, then simulated unrestrained for 30 ns. 
2.5 Apoptosis induction in intact cells 
2.5.1 Cell culture 
Mouse embryonic fibroblast (MEF) Bcl-x-KO cell line was kindly 
provided by Dr. Chi Li (University of Louisville, Louisville, KY) (110). Cells 
were maintained in DMEM (Thermo Scientific, SH30243.01) containing 10% 
FBS (fetal bovine serum) (Thermo Scientific, SH30070.03) supplemented with 
1X pen-strep (Gibco 15140-122). Cells were routinely tested to verify that they 





2.5.2 Generation of cell lines 
Full length human Bcl-xL cDNA and single point mutation Bcl-xL 
mutants (generated by using QuickChange II XL Site-Directed Mutagenesis kit 
from Agilent Technologies, # 200521-5 and verified by DNA sequencing) were 
cloned into the GFP (green fluorescent protein) expressing mammalian 
expression retroviral vector MIGRX EcoRI/XhoI to generate MIG-Bcl-xL or 
MIG-Bcl-mutant plasmids. MEF Bcl-xL-KO cells were infected with viruses 
expressing these mutants and infected cell populations were selected by sorting 
of GFP expressing cells by flow cytometry to generate stable cell lines. 
Presence of Bcl-xL WT and mutants in MEF-Bcl-xL-KO stable cell lines was 
confirmed by western blot as described below. 
2.5.3 Western blot 
Cell pellets were collected and lysed in NP-40 lysis buffer (Boston 
BioProducts, BP-119). Protein concentrations were determined using BCA 
protein assay reagent (Pierce #23223 and #23224). Twenty micrograms of 
protein samples were loaded on a 4-12 % Bolt Bis-Tris Plus gel (Life 
Technologies, BG04120BOX) and transferred to PVDF membrane (Bio-Rad, 
#162-0177). Membranes were blocked in TBS-T with 5 % milk for 1 hour at 
room temperature. Membranes were incubated overnight at 4°C with primary 
antibodies; anti-Bcl-xL (54H6) (Cell signaling, # 2764), anti-GFP (Abcam, 
ab6673) and anti-tubulin (Sigma Aldrich, #T5168) at 1: 20,000 dilutions. Anti-
mouse and anti-rabbit peroxidases labeled secondary antibodies were added at 





detection was performed using Pierce ECL Western Blot Substrate (Thermo 
Scientific, #32106). 
2.5.4 Cell Viability Assay 
MEF cells were cultured in 96- well plates (2,500 cells per well) 
overnight and then treated with different apoptotic stimuli at indicated drug 
concentrations for 24 hours. Cells were then incubated with 10% Alamar Blue 
reagent (Invitrogen, DAL1100) for 4 hours and the fluorescence of Alamar Blue 
reduction was determined using BioTek HT Synergy plate reader (540 nm 
excitation, 594 nm emission). Relative viability of treated cells was calculated 
by normalizing to vehicle treated cells. For bar graphs, relative cell viability 
was presented as normalized with respect to WT at that dose of a drug. Cisplatin 
(# 4394), Thapsigargin (# T9033), Etoposide (#, E1383) and Gemcitabine (#, 
G6423) were purchased from Sigma. Hydrogen peroxide was purchased from 
Fisher scientific (# H325-100). Doxorubicin (#,15007) was purchased from 
Cayman chemical company. Bortezomib was purchased from ChemieTek (#, 
CT-BZ001). All treatments were done in triplicate and each graph shown is a 
representative experiment of at least three biological replicates. Statistical 
analysis was performed using one-way ANOVA with Tukey’s test. p < 0.05 





2.6 Permeabilization of planar phospholipid membranes  
2.6.1 Preparation of E. coli extracts 
The desired E. coli strain was inoculated in 40 ml Terrific Broth medium 
without antibiotics and shaken at 37 oC overnight. The overnight culture was 
transferred to 1 L Terrific Broth without antibiotics and shaken until an OD of 
1.4 was reached. After sedimentation of the cells by centrifugation (5,000 g, JS-
4.2 rotor), the cells and the culture medium were collected. Cells were 
resuspended in 30 ml of 100 mM NaCl, 50 mM Tris, pH 7.3. The resuspended 
cells were aliquotted and stored at -20 oC.  
Five mL of resuspended cells were thawed. Protease inhibitors, 
including PMSF (36 M in final concentration) and complete EDTA free 
protease inhibitor (Roche), were added. Cells were lysed by two passages 
through a French Press. To remove the unbroken cells, the lysate was spun at 
8,500 g for 20 minutes. The cell-free solution was spun at 180,000 g (MLA-
130) for one hour to separate the soluble fraction from particulates like 
membrane vesicles. The pellet fraction was shaken with 5 ml of 50 mM Tris, 
pH 7.3, 2 % n-laurylsarcosine (w/v), and protease inhibitors at room 
temperature for two hours to dissolve inner membrane proteins. The mixture 
was spun at 180,000 g (MLA-130) at 4 oC for four hours. The supernatant 
containing the proteins in the inner membrane was collected. The pellet was 






The mixture was spun at 180,000 g at 4 oC for one hour. The supernatant 
containing the solubilized proteins from the outer membrane was collected for 
further analysis.  
2.6.2 Planar phospholipid membranes 
Solvent-free planar phospholipid membranes were formed by the 
monolayer method as previously described (111, 112). Two Teflon hemi-
chambers were separated by a thin and non-conducting polyvinylidene chloride 
(PVDC) partition containing a 100-µm diameter hole across which the 
membrane was formed (Fig 2.1). The area around the hole was coated with a 
thin layer of petrolatum using a 5 % petrolatum (w/v) in petroleum ether.  The 
aqueous solutions generally consisted of 1.0 M KCl, 1 mM MgCl2, 5 mM 
PIPES, pH 6.9. Monolayers were formed by layering 30 – 60 µl of the lipid 
Figure 2.1. Schematic presentation of planar phospholipid membrane setup. 
Two Teflon hemi-chambers are separated by a PVDC partition. The tans side is 
maintained at virtual ground by the amplifier. The aqueous levels can be adjusted 





solution (0.5 % diphytanoyl phosphatidylcholine, 0.5 % asolectin (polar extract 
of soybean phospholipids) and 0.05 % cholesterol in hexane) on the surface of 
each aqueous solution. Once the hexane had evaporated the levels of the 
solutions were raised above the hole thus forming a phospholipid bilayer 
membrane across the hole. Calomel electrodes with saturated KCl bridges were 
used to interface with the aqueous phase. The electrode in trans side was 
virtually ground by the amplifier. Therefore, the potential applied to the cis side 
was the transmembrane potential.  
  The E. coli extracts were pretreated with 1 % ß-octylglucoside (w/v) 
for 10 min on ice and then 15 µl of the extracts was successively dispersed in 5 
ml aqueous solution in cis side while stirring until a channel inserted. The 
membrane voltage was clamped using a high quality operational amplifier 
wired in the inverted mode with an adjustable feedback resistor (typically 108 
Ω resistance was selected) and the current was recorded using a Digidata 1322A 
digitizer and Clamplex 10.3 software (Axon Instruments). The constant voltage 
(above -70 mV) helped the insertion or formation of channels. Once a channel 
formed, voltage ramps (-70 mV to 70 mV) were applied to investigate the 
behavior of the channels. This allowed for quantitating the rectification of all 3 
channels together. Then a positive voltage (above 70 mV) was applied in order 
to close the channel 1. The same triangular ramp was applied resulting in 
channel 2 gating. In this recording for part of it channel 2 and channel 3 are 





70 mV) was applied to close channel 3 resulting in only channel 2 being open. 
This allowed a quantification of the rectification of channel 2 alone. 
2.6.3 Data Acquisition, correction and calculation 
Before the addition of E. coli extracts, the offset of voltage and current 
were adjusted or recorded. After the experiments, the electrode asymmetry was 
measured and recorded. These were used to make small corrections of the 
recordings. The conductance was plotted as the function of voltage. The 
rectification was quantitated as the slope of the conductance-voltage curve. All 






Chapter 3: Ceramide Channels: Destabilization by Bcl-
xL and Role in Apoptosis 
3.1 Abstract 
 Ceramide is a bioactive sphingolipid involved in mitochondrial-
mediated apoptosis. Our data suggest that ceramides directly regulate a key 
initiation step in apoptosis: mitochondrial outer membrane permeabilization 
(MOMP). MOMP allows release of intermembrane space proteins to the 
cytosol, inducing the execution of the cell. Ceramides form channels in planar 
phospholipid membranes and outer membranes of isolated mitochondria, 
channels large enough to facilitate passage of proteins released during MOMP. 
Bcl-xL inhibits MOMP in vivo and inhibits the formation of ceramide channels 
in vitro. However, the significance of Bcl-xL’s regulation of ceramide channel 
formation within cells was untested. We engineered Bcl-xL point mutations that 
specifically affect the interaction between ceramide and Bcl-xL to probe the 
mechanism of ceramide channel regulation and the role of ceramide channels 
in apoptosis.  Using these mutants and fluorescently-labeled ceramide, we 
identified the hydrophobic groove on Bcl-xL as the critical ceramide binding 
site and regulator of ceramide channel formation. Bcl-xL mutants with 
weakened interaction with ceramide also have reduced ability to interfere with 
ceramide channel formation. Some mutants have similar altered ability to 
inhibit both ceramide and Bax channel formation, whereas others act 





relative importance of these channels in apoptosis, Bcl-xL mutant proteins were 
stably expressed in Bcl-xL deficient cells. Weakening the inhibition of either 
Bax or ceramide channels decreased the ability of Bcl-xL to protect cells from 
apoptosis in a stimulus-dependent manner.  These studies provide the first in 
vivo evidence for the role of ceramide channels in MOMP. 
 
3.2 Introduction 
The release of mitochondrial intermembrane space (MIS) proteins into 
the cytosol is a key decision-making step in the apoptotic process. The released 
proteins initiate the execution phase of apoptosis via a series of steps that 
ultimately lead to the activation of caspases, specific proteases that lead to the 
transformation of the cell into apoptotic bodies that are engulfed by phagocytes.  
Various mechanisms exist by which proteins can be released from the MIS (77, 
113–115). Some of these involve the formation of large channels in the 
mitochondrial outer membrane (MOM). Two such channels are formed by 
either the translocation to the MOM and oligomerization of a cytosolic protein 
called Bax or the self-assembly of a MOM lipid called ceramide (5, 11, 14, 116, 
117).  Bax is a member of the Bcl-2 family of proteins that regulate apoptosis 
(118–120).  Both Bax and Bak are pore-forming proapoptotic members of this 
family.  Ceramide is a pore-forming member of the sphingolipid family of cell 
lipids, some of which are involved in the apoptotic process (121).  The functions 
of Bax, Bak and ceramide are interdependent in a number of ways. In some 





(122, 123). The Bak protein is required for ceramide synthase-dependent long-
chain ceramide synthesis during apoptosis (124).  There is evidence for synergy 
between Bax and ceramide in MOM permeabilization (MOMP) in isolated 
mitochondria (85, 125).   
The role of Bax in MOMP is well established (120), although the 
structure of the Bax channels is only poorly understood (126). Ceramide’s role 
in inducing apoptosis is also widely acknowledged (127, 128), although its 
ability to directly form channels in the MOM is still viewed with skepticism. 
Published work strongly supports the ability of ceramide to form channels in 
the MOM at physiologically relevant concentrations (77).  Ceramide forms 
large channels (typically 10 nm in diameter) in phospholipid membranes 
lacking proteins and these have been visualized by electron microscopy (78).  It 
has also been shown to release a variety of MIS proteins from isolated 
mitochondria while not releasing matrix proteins (11). Functional studies (79) 
and molecular dynamic (MD) simulations (80) support a model of the ceramide 
channels that consists of barrel-like structure whose staves are membrane-
spanning strings of ceramide molecules organized in an anti-parallel manner 
(Fig. 1.6). These thin-walled pores behave like elastic discs that can be 
deformed but will regain their natural structure after relaxation (129).  Yet all 
evidence indicates (11) that they are in dynamic equilibrium with ceramide 
monomers or non-conducting ceramide assemblies.  Thus, there is a great deal 





The formation of both Bax and ceramide channels is inhibited by the 
anti-apoptotic protein, Bcl-xL (17, 33). Whereas, it is generally agreed that Bcl-
xL inhibits Bax channel formation by forming heterodimers with activated Bax 
monomers (33, 130), the mechanism by which Bcl-xL inhibits ceramide 
channels is not well understood. Since ceramide channels are large assemblies 
of ceramide monomers, there is no precedent to indicate possible mechanisms 
by which such a structure could be prevented from forming or be destabilized 
by a protein although a mechanism has been proposed (81).  Experiments with 
ceramide analogs demonstrated that the hydrophobic tails of ceramide are 
important for the inhibition by Bcl-xL (81).  In addition, small molecule 
inhibitors (2-methoxyantimycin A3, ABT-737 and ABT-263), known as BH3 
peptide mimetics because they bind to a hydrophobic grove on Bcl-xL and thus 
block its ability to bind to Bax, were also found to inhibit the ability of Bcl-xL 
to inhibit the formation of ceramide channels in the MOM (81). These inhibitors 
interfere with the anti-apoptotic activity of Bcl-xL (44, 131, 132) suggesting 
that the ability of Bcl-xL to interfere with ceramide channel formation may 
somehow be linked to its anti-apoptotic function. Here we provide insight into 
the molecular basis by which Bcl-xL acts to inhibit ceramide channels by 
providing evidence for direct binding and using point mutations to identify the 
region on Bcl-xL responsible for the inhibition. These same Bcl-xL mutants 
were expressed in cells lacking Bcl-xL to assess the importance of ceramide 







Previous studies demonstrated that Bcl-xL inhibits ceramide channel 
formation in isolated mammalian mitochondria (17, 81). In addition, the use of 
ceramide analogs indicated that the hydrophobic regions of ceramide are 
important for this action of Bcl-xL (81). To distinguish between direct and 
indirect action, it would be desirable to determine whether Bcl-xL binds a 
ceramide channel. However, direct binding studies are not possible because 
ceramide channels are in dynamic equilibrium with ceramide monomers (11) 
and thus cannot be isolated and purified. The possibility of examining the 
binding of Bcl-xL to ceramide channels formed in liposomes is also not feasible 
because Bcl-xL binds to membranes regardless of the presence of ceramide 
channels and current methods of generating ceramide channels in liposomes 
cause only partial release of contents indicating that only one channel is formed 
per liposome (73, 133). Thus any binding studies would be plagued by very low 
signal to noise ratios. An alternative method is to determine whether a ceramide 
molecule is capable of binding to Bcl-xL. The binding of a ceramide molecule 
to Bcl-xL may mimic the binding between Bcl-xL and ceramide channels. 
3.3.1 Binding of ceramide to Bcl-xL 
Binding studies between Bcl-xL and ceramide are complicated by the 
physical properties of ceramide. Ceramide is inherently insoluble in water and 
Bcl-xL cannot be expected to function normally in an organic solvent. 
Therefore, an equilibrium binding experiment is not possible. However, when 





ceramide molecules exist transiently in aqueous solution and these can either 
bind to Bcl-xL or combine with each other to form micelles. If the Bcl-
xL/ceramide complex is formed it is unlikely to dissociate because of 
ceramide’s insolubility in water. Thus the complex should be stable and can be 
detected. However, a binding constant cannot be determined. Thus 
fluorescently-labeled ceramide (C11 TopFluor ceramide) was dispersed into a 
solution containing Bcl-xL (Fig. 3.1A). Any fluorescent ceramide that does not 
bind must form micelles. The fluorescent ceramide micelles were removed by 
centrifugation taking advantage of the fact that the density of the micelles is 
Figure 3.1. Fluorescently-labeled ceramide binds to Bcl-xL. A. Separation of 
fluorescently-labeled ceramide bound Bcl-xL from ceramide micelles. F1 is 
fluorescently-labeled ceramide: C11 TopFluor ceramide. B. Fluorescence spectrum 
of final sample from the separation shown in “A” (see methods for details).  “WT” 
indicates the medium contained wild-type Bcl-xL and fluorescence was due to 
bound fluorescently-labeled ceramide. “buffer” indicates that there was no Bcl-xL 
in that separation procedure.  The lack of fluorescence indicates that the procedure 






less than. that of the aqueous solution and this difference was increased by using   
10 % sucrose. The fluorescence of the subphase was recorded. In the absence 
of Bcl-xL, the centrifugation cleared the solution of ceramide micelles resulting 
in no detectable fluorescence. However, in the presence of Bcl-xL substantial 
fluorescence was recorded (Fig. 3.1B). The results indicate that the ceramide 
molecule binds to Bcl-xL directly. 
3.3.2 Determination of the location of the binding region on Bcl-xL 
Previous studies showed that drug molecules that bind to hydrophobic 
groove on Bcl-xL (ABT-263 and ABT-737) interfered with the protein’s ability 
Figure 3.2. A. One docking pose of ceramide on the crystal structure of Bcl-xL. 
The amino acids to be mutated are illustrated (yellow). Ceramide is in green with 
the two chains specified.  The ceramide amide linkage is in the middle with the 
amide nitrogen in blue and the carbonyl oxygen in red. The pose was obtained from 
the publication of Perera et al., 2012 (81).  B. Permeabilization of the MOM to 
cytochrome c estimated by measuring the initial rate of oxidation of added 
cytochrome c (24.7 µM final). To 730 µL of 0.25 mg/mL rat liver mitochondrial 
suspension was added 15 µL of either isopropanol (iso) or C16 ceramide (cer). The 
results were normalized by the absorbance of cytochrome c at zero time. WT, 
F105Q, R100L indicated that mitochondria had been preincubated for 5 min with 





to inhibit ceramide channel formation (81). Thus this region of Bcl-xL is a good 
candidate for the putative binding site by which Bcl-xL inhibits ceramide 
channels. To identify residues in the hydrophobic groove that may be important 
in regulation of ceramide channels, molecular docking of a ceramide molecule 
to Bcl-xL was conducted and two low-energy modes were used (pose1 and 2) 
(81) (Fig 3.2A). Single amino acid substitutions were made so as to change the 
strength of the interaction at the putative docking sites. Changes in charge 
(E96L and R100L), polarity (F97Q, F105Q, V126Q), and physical volume 
(V126W, F146A, Y195A) were engineered into full-length Bcl-xL (Fig. 3.2A). 
These were tested in isolated mitochondria for their ability to interfere with 
ceramide channel formation.  
As illustrated in Fig. 3.2B, the amount of reduced cytochrome c in the 
medium decreased as the added mitochondria oxidized the protein. The 
cytochrome c could only be oxidized if it could cross the outer membrane and 
bind to cytochrome c oxidase on the outer surface of the inner membrane. Thus 
the rate of oxidation of the cytochrome c is related to the degree of   MOMP by 
ceramide channels. The baseline rate of oxidation occurred when the vehicle 
(isopropanol) was added to the mitochondria. When ceramide dissolved in 
isopropanol was dispersed into the mitochondrial suspension, the   rate of 
oxidation increased. This rate was diminished by the presence of Bcl-xL in the 
medium. Many of the altered proteins had lost some of their ability to inhibit 
ceramide-induced MOMP, but one mutant was actually a more potent inhibitor 





were performed at two levels of added Bcl-xL protein: a low level resulting in 
a weaker inhibition (i.e. a greater ceramide-induced MOMP) to detect mutant 
proteins that had a stronger inhibition than the wild type, and a high level to 
detect mutants with a weaker inhibitory affect. Figs. 3.3A and 3.3B show the 
measured % inhibition for one set of experiments using 0.72 and 2.1μM Bcl-xL 
protein, respectively. Note that the stronger inhibitory effect of V126Q was only 
Figure 3.3. The inhibitory potency of Bcl-xL mutants on ceramide channels 
formed in isolated mitochondria. The final concentration of added Bcl-xL or 
mutant proteins was 0.72 µM (A) and 2.1 µM (B). C. Relative inhibition of 
ceramide induced MOMP by Bcl-xL mutants. The inhibitory ability is expressed 
relative to that of the wild-type so that if it is the same as the wild type the result 
would be 1. The statistically significant differences from the potency of the wild-





detected at the lower concentration and the weaker inhibitors were apparent at 
the higher protein concentration. Since experiments with wild-type and mutant 
Bcl-xL were performed in parallel, the level of inhibition of the ceramide 
channels was normalized to that of the wild-type protein (Fig. 3.3C) and then 
data from independent experiments were pooled and averaged. This 
normalization was necessary because the potency of the Bcl-xL varied from one 
batch of isolated mitochondria to another. The data for the enhanced inhibition 
came from the low Bcl-xL concentration experiments whereas the data for the 
reduced inhibition came from the high concentration experiments. The mutants 
are organized in a pattern reflecting their location on the docking site (Fig. 
3.2A). The results follow a distinct pattern.  
All but one of the mutants (E96L) were able to inhibit the formation of 
ceramide channels, the difference being the amount of protein needed to 
achieve the same level of inhibition. Thus perhaps E96 is such a critical site that 
removal of the carboxyl group results in failure to bind ceramide. V126W was 
nearly as effective as the wild-type, as expected from the mild change in the 
structure of the side chain. The inhibition capability of F97Q, R100L, F105Q, 
F146A and Y195A was weaker than that of the wild type whereas the capability 
of V126Q was stronger. From the docking pose, R100 hydrogen bonds with the 
C3 hydroxyl of ceramide. The same was seen in the MD simulations (Fig. 3.4). 
The hydroxyl group of tyrosine 195 interacts with the carbonyl of ceramide in 
the docking experiment whereas the MD simulations show intimate dipole-





1.6A). Thus the weaker interaction of these mutations correlates with the 
structural information provided by the MD simulations. F97Q, F105Q and 
F146A disrupted hydrophobic interactions suggesting that these residues 
interact with the hydrophobic tails of ceramide. These results agree with one of 
the Bcl-xL/ceramide binding poses identified in the docking studies. In the MD 
simulations, these three residues form the major portion of the hydrophobic 
surface that interacts with the ceramide acyl chain again confirming the 
importance of retaining these apolar surfaces (Fig. 1.6B). 
3.3.3 Correlation between the quantum yield of fluorescent ceramide 
bound to Bcl-xL mutants and their ability to inhibit MOMP 
The Bcl-xL mutants were tested for their ability to bind fluorescently-   
labeled ceramide as was performed in Fig. 3.1. Direct binding measurements 
did not yield satisfactory results for 2 reasons: 1) The variability in the ceramide 
Figure 3.4 Structure of C16-ceramide (green) bound to wild type Bcl-xL (ribbon 
mode) after 30 nsec of molecular dynamics simulation. a. Interactions between F97, 
F105 and F146 (in CPK labeled as “F”) and the acyl chain of ceramide (also in 
CPK). Note the intimate contact between these side chains and the hydrophobic tail 
of ceramide. b. Interactions between ceramide hydroxyls (shown in CPK and 
labeled with arrows) and R100 and Y195 (side chains in CPK). R100 has 2 
hydrogen bonds with the oxygen of the hydroxyl on carbon 3 of ceramide (labeled 
as 3-OH). The hydroxyl of Y195 (labeled as “Y”) is aligned next to the C1 hydroxyl 





dispersion process resulted in variable amounts of binding. 2) The 
unidirectional nature of the binding process in aqueous solution means that 
changes in the rates of dissociation could not affect the amount of binding.  
However, in attempting these experiments it was noted that fluorescently-
labeled ceramide bound to mutated Bcl-xL produced much less fluorescence 
than the same ceramide bound to wild-type Bcl-xL. Fig. 3.5A shows the 
reduction of ceramide fluorescence upon binding to Bcl-xL.  The solid circles 
show the spectrum of the ceramide bound to the Bcl-xL, whereas the open 
circles show the spectrum after extraction with isopropanol. These relative 
values were adjusted for the volume of the solution.  The reduction in 
fluorescence is probably the result of exposing the fluorophore to a polar 
environment that quenches the fluorescence. Fig. 3.5B shows the fluorescent 
intensity of the same amount of ceramide bound to either wild-type Bcl-xL or 
Bcl-xL mutants.  This difference is most likely due to greater interaction of the 
fluorophore with water.  In a tight-binding situation water will have less contact 
with the fluorophore and thus result in less quenching. There is a good 
correlation between the intensity of the measured fluorescence and the potency 
of the mutant (Fig. 3.5C) to destabilize ceramide channels.  These results 
indicate that binding of Bcl-xL to the ceramide channel was the basis for the 
inhibitory effect and thus the ceramide channel was being directly controlled 





3.3.4 Molecular dynamic simulations of ceramide binding to Bcl-xL 
Wild type Bcl-xL and 5 mutants (E96L, R100L, F105Q, V126Q and 
Y195A) that span the range of abilities to inhibit ceramide permeabilization of 
the MOM, were examined using MD simulations to explore their interaction 
with a C16-ceramide molecule. In the first few nanoseconds of simulation the 
Figure 3.5. A. Fluorescence spectrum of C11 TopFlour bound to Bcl-xL (WT + 
Cer), C11 TopFlour extracted with isopropanol (WT extracted), and controls 
lacking Bcl-xL. B. Fluorescence spectrum of C11 TopFlour bound to wild-type 
Bcl-xL (WT) and to various Bcl-xL mutants. The curves were normalized by the 
fluorescence of the extracted fluorescent ceramide.  Thus changes in fluorescence 
intensity were due to reductions in the quantum yield due to some quenching 
process. C. Correlation between the quenching of fluorescent ceramide bound to 
Bcl-xL mutant protein and the ability of the same protein to inhibit ceramide 





ceramide found its optimal position in the Bcl-xL hydrophobic pocket and from 
then on the positions varied according to local interactions with the Bcl-xL 
protein and the water environment. All the introduced mutations are among the 
residues that are likely to interact with ceramide; they do not participate in any 
significant inter-helical interactions that maintain protein fold. Therefore, the 
mutants are not likely to affect the protein structure itself. Indeed, in simulations 
the structure of the ceramide-binding region of Bcl-xL changed very little in the 
mutants compared to the wild-type (0.15 ± 0.04 nm all-mutant mean deviation 
of the backbone from the WT position) indicating that the mutations acted 
locally, on the protein-ceramide interactions rather than globally, through a 
Figure 3.6. An example of the dynamic motion of the ceramide molecule in the 
hydrophobic groove of Bcl-xL. Illustrated is wild-type Bcl-xL and 30 locations (1 
nsec apart) of the C16-ceramide molecule (thin lines). The acyl and sphingosyl 






change in the protein structure. However the results showed considerable 
changes in the location and dynamics of the bound ceramide –1.0 ± 0.3 nm all-
mutant mean deviation of ceramide from its average position in WT Bcl-xL The 
dynamic motion of the ceramide molecule (Fig. 3.6) correlates very well with 
the loss of ability to inhibit ceramide permeabilization (Fig 3.7, Table 3.1), i.e. 
ceramide channel formation. The highest correlation was observed when the 
distal half of the sphingosine acyl chain was excluded. The fluorophore label 
experiencing more quenching with reduced inhibitory ability of the Bcl-xL 
mutant agrees with the simulation findings of greater mobility. Greater mobility 
should result in more access to water dipoles and thus more water-induced 
quenching. Note that the fluorophore is on the fatty acyl chain whose mobility 
correlates well with loss of Bcl-xL inhibitory ability.  
The relative location of the ceramide on Bcl-xL compared to the wild-
type also correlates, although more weakly, with the loss of inhibitory ability. 
This is reasonable as a change in location could influence the ability of the 






     
Figure 3.7 Correlation between the dynamic motion of the ceramide molecule 
and the ability of a Bcl-xL mutant to inhibit ceramide permeabilization of the 
MOM. The mobility (RMSF) of regions of the ceramide molecule (inset) were 
measured. Those regions surrounded by a solid line are plotted as a solid line in the 
main figure. Similarly for the dotted and dashed line. The inhibitory ability 
(horizontal axis) is expressed relative to that of the wild-type so that if it is the same 
as the wild type the result would be 1. 
Table 3.1. Correlation between the dynamic motion (RMSF) of different regions of the 
ceramide molecule and the ability of Bcl-xL to inhibit ceramide permeabilization of the 
MOM  
Mobility Deviation from wild type 
Location Correlation Location Correlation 
Ceramide without 
sphingosine tail after C10 
-0.96 Ceramide amide oxygen -0.63 
Ceramide up to C10 and 
C8’ 
-0.96 Ceramide polar atoms -0.60 
Ceramide amide tail C9’-
C16’ 
-0.91 Ceramide headgroup -0.59 
Ceramide whole -0.78 Ceramide fatty acid 
residue 
-0.57 
Ceramide tail C10-C8’ -0.57 Ceramide amide tail -0.54 
Bcl-xL  -0.09 Ceramide whole -0.24 
Bcl-xL in contact with 
Ceramide 






3.3.5 Comparison of the binding footprint on Bcl-xL of Bax and the 
ceramide channel 
Bcl-xL is known to inhibit the formation of Bax channels in the 
mitochondrial outer membrane. The hydrophobic pocket of Bcl-xL binds the 
BH3 domain of pro-apoptotic proteins such as Bax and Bid (27, 28, 51) and 
thus inhibits their pro-apoptotic activity, including channel formation. The Bcl-
xL mutants were tested for their effects on Bax channel formation in the MOM 
to determine if their relative potency is similar to that observed for ceramide 
channels. A complicating factor is that truncated Bid (t-Bid) is necessary to 
activate Bax resulting in MOMP and thus one cannot distinguish between an   
inhibitory effect on Bax or on t-Bid. Regardless of which protein binds to Bcl-
xL, the mutants will probe whether the same region of Bcl-xL is used in both 
cases. Once again, in order to achieve a greater dynamic range, the amount of 
wild type protein added was adjusted to obtain a weaker (Fig 3.8A) or a stronger 
(Fig. 3.8B) inhibition. The results show that V126Q and Y195A have a stronger 
inhibitory effect than the wild-type. F146A, R100L, V126W, F105Q, F97Q and 
E96L have a weaker inhibitory effect. As in the case of the ceramide channel, 
E96L has no effect. A comparison of the inhibitory effects of mutated Bcl-xL 
on Bax (Fig. 3.8C) and ceramide channels (Fig. 3.3C) reveals that two 
mutations have distinctly different effects on the two channels. A plot of one 
set of data vs the other (Fig. 3.9) shows that Y195A has stronger inhibition of 





effect on ceramide channels. V126W was not able to inhibit Bax channels as 
well as the wild type, but had the same ability to inhibit ceramide channels as 
the wild type. This information could be used to distinguish between apoptosis 
resulting from MOMP due to activated Bax or ceramide. 
Figure 3.8. The inhibitory potency of Bcl-xL mutants on Bax permeabilization 
of the MOM. The final concentration of added Bcl-xL or mutants was 0.72 µM (A) 
and 0.86 µM (B). C. Relative inhibition of Bax permeabilization of MOM by Bcl-
xL mutants. The inhibitory ability is expressed relative to that of the wild-type so 
that if it is the same as the wild type the result would be 1. The statistically 





3.3.6 Probing the relative importance of ceramide and Bax channels in 
apoptosis in intact cells 
Both ceramide and Bax form channels that release proteins from the 
MIS. These two agents also act synergistically to induce MOMP (85). However 
it is unclear which channel-former is used in vivo.  The Bcl-xL mutant proteins 
were expressed in cells lacking Bcl-xL in order to obtain some insight into this 
question. Cells expressing either wild type or one of three mutants (Y195A, 
V126Q, and V126W) were stimulated to undergo apoptosis using 7 different 
chemical stimuli (cisplatin, gemcitabine, hydrogen peroxide, thapsigargin, 
doxorubicin, etoposide, or bortezomib) that activate different apoptotic 
pathways.  A comparable level of expression of mutant proteins was achieved 
and a dose response curve was performed for all of the above stimuli. Fig. 3.10 
shows an example of the dose-response curves.  Two doses were selected for 
detailed statistical analysis, one in the transition region between no drug effect 
and the full effect and another immediately after a maximal effect of the 
chemical agent was achieved.     
V126W inhibits ceramide channels as well as wild-type Bcl-xL (Fig. 
3.11) but has only half the potency on Bax channels.  In most cases, this mutant 
was less effective than the wild-type in protecting cells from apoptosis, 
consistent with the important role of Bax channels in the apoptotic process.  
V126Q is more effective at inhibiting both Bax and ceramide channels (Figs. 
3.3 and 3.8); cells expressing V126Q were often more resistant to death stimuli 





peroxide, and thapsigargin high dose).  Y195A is also more potent at inhibiting 
Bax channels but only half as potent on ceramide channels (Figs. 3.3 and 3.8). 
Cells expressing Y195A were more sensitive to gemcitabine (low dose), 
doxorubicin (high dose), and bortezomib (low dose) than cells expressing 
V126Q even though Y195A is a more potent inhibitor of Bax channels (Fig. 
3.11 and 3.11). In the case of the high dose of bortezomib, cells expressing 
Y195A are more sensitive than cells expressing the wild-type Bcl-xL (Fig. 
3.11B). The results with Y195A provide evidence for the role of ceramide 
channels in cells treated with these compounds.  In other cases, such as 
thapsigargin treatment, the weaker ability of Y195A to inhibit ceramide 
channels had no effect as the cell viability observed with cells expressing 
V126Q and Y195A were not different.  Thus ceramide channels may play a role 





Figure 3.11. A. Relative viability of cell expressing the indicated Bcl-xL and 
induced to undergo apoptosis with the indicated amount chemical agent. The 
significant differences are indicated as follows: *, compared to empty vector; #, 












The surprising ability of a lipid, ceramide, to form large, and stable 
channels in phospholipid membranes was initially met with skepticism. Now 
the evidence supporting the existence of ceramide channels is overwhelming.  
This includes recording their properties in defined planar phospholipid 
membrane systems (10, 79), visualization by electron microscopy (78), 
demonstration of the stability of the ceramide channel model by molecular 
dynamic simulations (80), and examination of the elastic properties of these 
channels by microfluidic methods (129).  The role of these channels in 
apoptosis was indicated by the ability of ceramide to permeabilize the MOM to 
proteins even when the source of the mitochondria was the yeast, S. cerevisiae, 
an organism lacking the Bcl-2 family of proteins (17).  The evidence for this 
role was substantially increased by the findings that Bcl-2, Bcl-xL and CED-9 
all inhibit ceramide channel formation in isolated mitochondria (17) whereas 
Bax acts synergistically with ceramide to permeabilize the MOM (85). Further 
support of a specific regulatory role of ceramide channels by Bcl-2 family 
proteins was the finding that Bcl-xL acts by interacting with the hydrophobic 
region of ceramide whereas Bax preferentially interacts with the polar regions 
(81).  Here we actually identify the region of Bcl-xL that binds ceramide and it 
turns out to be a similar region to the one that binds Bax.   
The direct binding experiments used fluorescently-labeled ceramide as 
a surrogate for ceramide channels.  The ability of Bcl-xL to bind ceramide 





the free ceramide concentration, rather than binding to the ceramide channel. 
However, the amount of ceramide added to the mitochondrial suspension was 
25 to 70 fold higher on a molar basis that Bcl-xL, making this possibility 
unlikely. Given that fact, one might wonder why the excess ceramide does not 
simply occupy all the sites on Bcl-xL and act as a competitive inhibitor, 
interfering with Bcl-xL binding to the ceramide channel.  The answer might 
reside in the observation that Bcl-xL binds to the acyl chains of ceramide and 
typically these are buried either in the membrane bilayer or in the core of 
ceramide micelles and are thus unavailable for binding to Bcl-xL.  However, 
according to the working model of the ceramide channel (Fig. 3.8), the ceramide 
molecules that form the channel are oriented parallel to the plane of the 
membrane and organized in columns that span the membrane.  The ceramides 
at the ends of these columns would have their hydrophobic tails exposed to the 
water phase were it not for these being covered by the surrounding 
phospholipids to minimize the unfavorable interactions with water. However, 
these phospholipids are in a distorted, high-energy conformation.  If Bcl-xL 
were to displace these lipids it would bind the hydrophobic tails of this ceramide 
and by doing so could change the structure of the channel.  According to the 
current hypothesis that describes how Bcl-xL binding destabilizes ceramide 
channels (81), the binding changes the curvature of the ceramide columns. MD 
simulations show that the columns have a positive curvature resulting in the 
channel having a somewhat hourglass shape.  This is due to the way the channel 





phospholipids that curve towards the channel to cover the hydrophobic ends of 
the ceramide columns are under stress and thus pull on the ceramide columns, 
bending them. Bcl-xL binding removes this bending force by displacing the 
phospholipids. This results in mismatch with adjacent columns still interacting 
with phospholipids and thus strain develops that propagates to the rest of the 
structure through the hydrogen-bonded network, thus destabilizing the entire 
structure. Mutations that weaken the binding of Bcl-xL to ceramide 
(fluorescence and MD simulations) should reduce the ability of Bcl-xL to 
destabilize ceramide channels and that was demonstrated in their reduced 
ability to inhibit ceramide permeabilization of the MOM. Altering the position 
of the ceramide-Bcl-xL interface, as indicated in the MD simulation, may alter 
the above hypothesized curvature change and thus the amount of strain and the 
degree of destabilization of the channel structure. This explains the correlation 
between a shift in the location of ceramide binding to mutant Bcl-xL and a 
reduction in the Bcl-xL’s ability to inhibit the ceramide-induced MOMP.    
The pro-apoptotic role of ceramide is well established (127, 128), 
whereas the in-vivo pro-apoptotic role of ceramide channels is not.  Not only 
do these channels have the right properties, but mitochondrial ceramide levels 
have been shown to increase early in apoptosis to levels sufficient to form 
ceramide channels. However, these finding do not demonstrate that cells 
actually use ceramide channels during apoptosis. Indeed, ceramide metabolites 
were reported (135) to activate Bax and Bak and induce MOMP.  In view of 





fact that cells lacking both Bax and Bak are very resistant to apoptosis.  But 
here again the simple conclusion is misleading, because cells lacking Bax and 
Bak also fail to increase mitochondrial ceramide levels (124), unlike the 
parental cells.  It turns out that Bak is required for ceramide synthase-mediated 
long-chain ceramide generation during apoptosis. Thus the situation is far more 
complex and a more direct approach is needed. Here we report experiments 
with mutants of Bcl-xL that have an altered ability to inhibit MOMP induced 
by either ceramide or Bax.  The results show that the ability of Bcl-xL to inhibit 
Bax channels is indeed, as expected, important for Bcl-xL to promote cell 
survival. However, when the ability of Bcl-xL to inhibit ceramide channels is 
reduced, the ability of Bcl-xL to protect cells from particular death stimuli was 
also reduced. This lack of protection from cell death in the mutant Bcl-xL 
occurred despite it being 15-fold more potent at inhibiting Bax channels.  Thus 
it seems that inhibiting Bax channels alone is insufficient for Bcl-xL to protect 
from apoptosis and that under certain conditions ceramide channels take over 
the role of releasing proteins from mitochondria.  Of course there are alternative 
explanations that seem less likely.  For instance if Bcl-xL were to facilitate the 
transfer of ceramide between membranes and this transfer were important to the 
progress of apoptosis then mutations that weaken the binding of Bcl-xL to 
ceramide would also weaken the propensity to undergo apoptosis. This 
hypothetical function would not explain the results with isolated mitochondria 





role of ceramide channels needs to be considered when interpreting 
experimental results. 
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Chapter 4: Insight into the structure and dynamics of 
channels by measuring rectification 
4.1 Introduction 
4.1.1 A novel channel discovered in E. coli extract  
Shang H Lin et al. found a steeply voltage-gated cation channel in 
Escherichia coli extracts (136). The steepness is remarkably high, rivaling that 
of channels in excitable membranes. In addition, the channel seems to exist as 
an assembly of three channels that are highly cooperative. The physiological 
function of such a channel is completely unclear, but the remarkable properties 
indicate an important regulatory role. Figure 4.1 shows the current model of 
how this channel functions. One channel unit consists of three cylindrical 
channels arranged in a row. The shading indicates the structural orientation. The 
middle channel (channel 2) is proposed to have an opposite orientation with 
respect to its neighbors (channel 1 and 3). The arrows indicate the dipole 
moment of the voltage sensor in each channel. An open circle on the top of each 
cylinder indicates an open channel and a filled circle indicates a closed channel. 
The positive and negative signs above the unit are the signs of the applied 
voltages. Note that the closure of one channel results in the realignment of the 
voltage sensor dipole with the electrical field but does not change the structural 
orientation. The channels have strong positive cooperativity. This means that 
channels prefer to be in the same conformation with the adjacent channels, i.e. 
all open or all closed. If channel 1 closes, it allows channel 2 to respond to 





closure of channel 2. The model explains this by illustrating the changes that 
occur following different experimental treatments. Channels remain open with 
a negative voltage applied and at low potentials (upper left in Figure 4.1). The 
closure of channel 1 is induced with a high positive voltage applied (typically 
Figure 4.1. Model of the highly cooperative and voltage-gated E. coli channels. 
Three cylindrical channels constitute a 4.5 nS conducting unit. The channels 
designated as channel 1, 2, and 3. The shading indicates the orientation of the 
channel. The orientation of channel 2 is opposite to its neighbors. The arrows show 
the dipole moment of each channels, originally from the distribution of gating 
charge. Open and solid circles on the top of cylinders show open and closed 
channels, respectively. Closure of channel results in the rearrangement of electric 
distribution of the channel, and changes the dipole moment. However, the 
orientation of each channel is still the same. Channel interacts with its adjacent 
channel cooperatively and prefers to have the same conformation as its neighbor, 
ie. both open or close. The sign at the upper right corner of each conducting unit 
indicates the applied voltage. The fast path indicates, using triangular ramps, the 
closure of channel 1 favors the close of channel 2, which occurs at negative 
voltages. Applying fast triangular voltage ramps and the kinetic delay of channel 2 
reopening result in channel 2 remaining closed and allowing channel 3 to close. As 
the voltage declines, either channel 3 reopens followed by channel 2 or channel 2 
and 3 reopen simultaneously. The slow path indicates the slow rate of closure. 
However, applying a high positive potential closes both channel 1 and 3, and then 
forces channel 2 to close through cooperativity with its neighbors. Reproduced with 
permission, from Lin SH, Cherian N, Wu B, et al., 2014, Bax channel triplet: co-






70 mV or above). The “slow” indicates a slow rate of closure when a constant 
positive voltage was applied. This is due to conflicting forces on the channel’s 
gating propensity. A high positive voltage induced the closure of channel 1 and 
3 in spite of inhibitory effects from the open channel 2. In addition, although 
channel 2 should not close at positive voltages, the cooperativity with the 
adjacent channels forces the closure of channel 2, despite the applied field 
favoring the open state. The “fast” pathway indicates what happens following 
the application of triangular voltage ramps. Channel 2 closes at low negative 
potentials because, in addition to the applied electric field, the closure of 
channel 1 results in an unfavorable dipole-dipole interaction. Channel 3 closes 
at low positive potentials only after the closure of channel 2 for the same reason. 
The model is based on several assumptions including (a) the triplet is 
composed of three identical proteins, having the same structure, each forming 
one channel, (b) the orientation of channel 2 is opposite to that of the adjacent 
channels, and (c) the dipole-dipole interactions between adjacent channels of 
the voltage sensors result in the cooperativity. Although it is possible that a 
different protein froms each one of the channels, several observations support 
assumption (a). The conductance of each channel is indistinguishable, the 
selectivity of each channel is the same, and the voltage dependence of channels 
2 and 3 seems the same.  
Assumption (b) seems problematic. It is almost unprecedented that the 
same protein should insert in two directions in the same membrane. Without 





However, we took a functional approach to address this question. To test 
whether the orientation of channels 2 is opposite to that of the adjacent 
channels, the rectification of the channels was measured. 
4.1.2 Rectification 
Rectification is a condition where a conductor does not obey Ohm’s law. 
Current flow in one direction is greater than that in the opposite direction 
despite the same voltage magnitude. In other words, the current-voltage 
relationship is non-linear or the conductance depends on voltage. A famous 
example of rectification in membrane channels is the inwardly rectifying 
potassium channel (Kir). Inwardly rectifying means that the flow of potassium 
ions in the inward direction (into the cell) is easier than flow in the outward 
direction (out of the cell). It plays an important role in regulating neuronal 
activity and in stabilizing the resting potential. In the cell, when the membrane 
potential is negative relative to the reversal potential of the channel, potassium 
ions flow into the cell and restore the resting potential. However, when the 
membrane potential would cause potassium ions to move out of the cell, 
endogenous polyamines, such as spermine, block the Kir channel, facilitating 
membrane depolarization.  
Rectification can be caused by either an external asymmetry, i.e. due to 
differences in the medium on the two sides of the membrane, or an internal 
asymmetry, one intrinsic to the channel’s structure. The latter provides 






4.2 Results and discussion 
The proposed anti-parallel orientation of the three channels in the triplet 
was tested by measuring the direction of the rectification of the current flowing 
through each channel. This rectification in the presence of symmetrical salt 
solutions across the membrane must be caused by an inherent asymmetry in the 
channels. In order to record the current rectification of individual channels, it is 
necessary to insert a single triplet into the planar membrane. A single triplet is 
composed of three highly cooperative and voltage gated channels (designated 
channel 1, 2, and 3) (Fig 4.1). All three channels have the same conductance, 
1.5 nS. Thus they cannot be distinguished using conductance measurements. 
They are distinguished by their voltage-gating behavior and this behavior 
allowed us to tease apart the current flowing through each. The gating model 
generated from previous studies (2) was used to apply a voltage protocol to 
close channels sequentially and identify the channel(s) whose current was being 
recorded. The application of voltage ramps to the membrane resulted in current 
records (e.g. Fig 4.2) from which the conductance was calculated. The 
rectification was quantified as the slope of the conductance-voltage curve.  
Typically a 10 to 30μL aliquot of the active fraction was dispersed into 
the aqueous phase on the cis side of the planar phospholipid membrane. After 
a variable lag time, the conductance increased. A conductance of 4.5 nS 
indicated the insertion or formation of a single triplet in the membrane, as 





voltage ramps (e.g. 8.3 mV/sec, from 70 to -67 mV) showed no voltage gating 
(first segment of Fig 4.2 and Fig 4.3A). Under this condition one is probably 
recording the current flowing  through all three channels simultaneously. This 
Figure 4.2. Voltage gating of a single triplet. Triangular voltage ramps (bottom 
panel) were applied to the membrane and the resulting current record (middle panel) 
and calculated conductance (upper panel) are shown. The segments from left to 
right are all channels open, only channel 2 gating  (channel 3 was open), channel 2 
and channel 3 gating, and channel 2 gating while others are closed, respectively. 
The frequency of the left two segments was 30 mHz (8.3 mV/sec) and that of the 






was usually the case but only became certain after gating was induced and 
normal behavior was observed. The rectification of current flowing through all 
three channels was measured as a slope in the conductance/voltage relation. An 
example of the results of this measurement is shown in Fig. 4.3A. When the 
current is divided by the applied voltage there is an artifact close to zero that 
should be ignored. To begin the gating process a constant high positive voltage 
(typically +70 to +90mV) was applied until a 1.5 nS drop of conductance was 
observed. This was the closure of channel 1. If the channel reopened, then the 
application of the high potential was repeated. Typically channel 1 adapted 
Figure 4.3. Pattern of a single triplet. A single triplet was probed by triangular 
voltage ramps. Cartoons show the status of channels described in Fig 4.1. A. When 
all three channels are opened, no voltage gating was observed. B. After the closure 
of channel 1, channel 2 gated at negative potential and reopened at nearly zero. C. 
Channel 3 closed at positive potential and reopened at nearly zero potential. D. After 
the closure of channel 1 and 3, channel 2 closed at a negative potential and reopened 





quickly to the closed state and did not reopen. Once channel 1 was closed, this 
allowed another channel to gate at low negative potentials. This was channel 2. 
It was the only one that reproducibly gated at negative potentials. Under these 
conditions channel 3 often remained open. This is illustrated in the second 
segment of Fig 4.2 and the sample result in Fig 4.3B. This gating of channel 2 
caused the conductance to alternate between 3.0 and 1.5 nS. Channel 2 closure 
occurred at around -27 mV with reopening taking place at a more positive 
potential due to kinetic delays. In the illustrated experiment the voltage was 
changed at a rate of 9.8 mV/sec, from +83 to -80 mV.  
As noted the closure and reopening of channel 2 took place at different 
potentials. This is due to the fact that the closing process is faster than the 
reopening process. This is also true of channel 3. Therefore, the voltage at 
which channels 2 and 3 reopen is highly dependent on the rate of voltage 
change. The kinetic delay of channel 2 reopening allowed us to set conditions 
that favored the closure of channel 3, because almost invariably channel 3 
closure did not occur until channel 2 was closed. The problem is that channel 3 
closure takes place at positive potentials, conditions favoring channel 2 
opening. By raising the frequency of the voltage ramp from 9.8 mV/sec to 65.6 
mV/sec, channel 2 often remained closed long enough for channel 3 to close 
(third segment of Fig 4.2 and the sample result in Fig 4.3C). Channel 3 gating 
took place around +28 mV with reopening occurring as the positive potential 
declined. Once channel 3 closes, the reopening of channel 2 is inhibited, 





 To study whether the orientation of channel 2 is opposite to that of the 
other channels, the rectification of channel 2 itself is required. Although channel 
3 is inhibited from closing when channel 2 is open, a high positive potential 
similar to that used to close channel 1 was used to close channel 3, leaving only 
channel 2 to conduct. This outcome was verified by noting that the remaining 
channel gated at negative potentials (fourth segment of Fig. 4.2 and the sample 
result in Fig. 4.3D). The closure of channel 2 occurred at around -27 mV with 
reopening at positive potentials.  
4.2.1 Rectification of channels 
Data was collected by measuring the current as a function of voltage 
using a variety of rates of change of voltage. This raises the question as to 
whether the rectification measured depends on the rate of voltage change. 
Membrane channel rectification generally arises from an asymmetric 
distribution of mobile charges within the channel. It does not involve changes 
in the structural state of the channel. The redistribution of free ions occurs at 
the nsec time scale and thus much faster than the rates of voltage change used 
in these experiments. Only the much slower conformational changes of the 
channel-former should be affected by the rates of voltage change used.  
However, it is possible that these channels are unusually compliant and their 
structure may be distorted by the applied electric field, up to 200,000 Volts per 
cm. This possibility was tested (Fig. 4.4B) and no significant change was 





Some channels adapt to the applied electric field and it is possible that 
the application of a long set of voltage ramps might result in changes in the 
structure of the channels and thus changes in the value of the rectification. The 
possibility of such time-dependent effects was tested. The results indicate that 
the rectification and the conductance did not dependent on time after initiating 
Figure 4.4. Independence of channel rectification on time or the rate of voltage 
change. The rectification (A) and conductance (B) of channel 3 were independent 
of time following a series of recordings. (C) The rectification of channel 2 +3 





a sequence of voltage ramps (Fig. 4.4A and B). Thus it was possible to combine 
the rectification values calculated from each ramp to obtain an average value. 
The measurements of rectification are expressed as changes in the 
conductance in nanoSiemens per 100 Volt change in applied potential. This was 
done so that the values would be in a convenient numeric range. The results are 
shown in Table 4.1 and Fig. 4.6. The rectification of channel 1 + 2 +3 was -162 
± 8 nS/100V (mean ± S.E.), 11 measurements in 6 separate experiments (Fig 
4.5A). The quantification of the rectification of the combined channels 2 and 3 
yielded -82 ± 12 nS/100V, 10 measurements in 5 separate experiments (Fig 4 
.5B), and that of channel 3 was -89 ± 7 nS/100V, 10 measurements in 5 separate 
experiments (Fig 4.5C). The rectification of channel 2 was 2 ± 21 nS/100V, 4 
measurements in 2 separate experiments (Fig. 4.6D). All values collected are 
Figure 4.5. Rectification of a single triplet. A single triplet was probed by applying 
triangular voltage ramps. Cartoons show the state of channels as described in Fig 4.1. 





measurements in 2 separate experiments (Fig. 4.5D). All values shown 
collected are in Fig. 4.6 and.the calculated means and standard errors are shown 
in the inset and table 4.1. Only the rectification values for channels 2 and 3 were 
Figure 4.6. Rectification of channels from a variety of experiments. The main 
figure shows the rectification as a function of the conductance measured at low 
voltages.  Each point is the average result from one experiment.  The inset shows 
the average and the standard error for all data of one kind. Channel 1 + 2 + 3, 2 + 3, 
3, and 2 are shown in solid circle, empty circle, solid triangle, and empty triangle, 
respectively.  
Table 4.1 Measured and calculated rectification of each channel. Columns 2 and 
3 show the measured conductance and rectification averaged over all experiments 
(average ± standard error). The columns on the right show calculated values from 
the adjacent measured values as a test of self-consistency.  The calculated 
rectification was compared to the measured one using the Student’s T-test and the 























1, 2, 3 4.51 ± 0.09 -162± 8 -86 ± 12 
(P=0.60) 
    
2, 3 3.11 ± 0.10 -83± 12 7 ± 11 
(P=0.58) 
  -173 ± 17 
(P=0.70) 3 1.69 ± 0.09 -89± 7  -96 ± 28 
(P=0.65) 
-193 ± 41 







determined directly but even those measurements should be compared with care 
because they were determined in different regions of the voltage scale.  
4.2.2 Channel 2 has an orientation opposite to that of other channels 
  If the orientation of channel 2 is opposite to that of its adjacent channels 
and the structure of each channel is the same, the rectification of channel 2 
should be opposite to that of the others. Thus, the rectification when all channels 
are open should be the same as that when only either channel 1 or channel 3 is 
open. The rectification of channel 2 + 3 should be zero. The results, as 
summarized in Fig. 4.6 and Table 4.1, are not that straightforward but are 
largely self-consistent.  For instance, the difference between channel 2 + 3 and 
channel 3 is +7 ± 11 nS/100V, which is close to measured channel 2 (2 ± 21 
nS/100V) (P = 0.58). In addition, combing the rectification of channel 2 and 3 
yields -96 ± 28 nS/100V, which is not far away from the measured value, -83 ± 
12  nS/100V (p = 0.65). The rectification of channel 1 (-86 ± 12  nS/100V), 
which is the difference between channel 1 + 2 + 3 and channel 2 + 3, is similar 
to measured value of channel 3 (-89 ± 7 nS/100V) (P = 0.60). This result is 
consistent with the proposal that the orientation of channel 1 is the same as that 
of channel 3. We can add the rectification of channel 2 to twice that of channel 
3. This yields -193 ± 41 nS/100V, which is close to the measured value, -162 ± 
8 nS/100V (P = 0.74). We can also combine the measure value of channel 3 
with that of channel 2 + 3, and get a result of -173 ± 17 nS/100V which is 
essentially the same as the measured value, -162 ± 8 nS/100V (P = 0.70). The 





channel 1 and 3.  Indeed, this would be consistent with channel 2 being in an 
opposite orientation from channels 1 and 3 if there were some asymmetry in the 
system. An anomalous experiment supports this hypothesis. 
Table 4.2 Measured and calculated rectification in the anomalous experiment. 
Columns 2 shows the measured rectification (average ± standard error). The 
columns on the right show calculated values from the adjacent measured values as 





Calculated Rectification (nS/100V) 
Channels 
open 
 1 2 
23 123 123 
1, 2, 3 130 ± 14 
4 ± 24 
    
2, 3 126 ± 20 
121 ± 24 
  131  ± 24 
3 5 ± 14  100 ± 14 105  ± 14 
2 95    
 
 
Figure 4.7. Rectification of channels in an anomalous condition.  Illustrate the 
variation of rectification of each channel status in an anomalous condition. The inset 
shows the average and the standard error. Channel 1 + 2 + 3, 2 + 3, 3, and 2 are 





4.2.3 An asymmetrical surface potential changes the rectification of 
channels 
In one experiment, the rectification values were quite different but the 
results are still self-consistent as in the typical cases, arguing for some unusual 
asymmetry in this experiment.  In this experiment, as in the others, many 
measurements of the rectification of the channels were performed, thus the 
values reported are well substantiated. In this anomalous case, although the 
rectification values for the channels are different from the ones measured in the 
typical cases, the gating behaviors of channels are unchanged.  That is to say 
that channels 2 and 3 gated at the typical potentials both in sign and magnitude.  
Channel 2 still closed around -27 mV and channel 3 closed around +28 mV. 
Therefore, the orientation of this anomalous triplet was the same as that in the 
other experiments. The rectification values for channels 1 + 2 + 3, 2 + 3, 3 and 
2 were 130 ± 14, 126 ± 20, 5  ± 14, and 95 nS/100V, respectively (Table 4.2 
and Fig 4.7). The calculated rectification values of each channel state are close 
to those measured directly. The measured rectification of channel 3 is similar 
to the calculated one of channel 1 and different from that of channel 2. This 
result indicates that channel 3 has a similar structure as that of 1 but is 
fundamentally different from that of channel 2. This suggests that the 
orientation of channel 2 is opposite to that of channel 1 or 3. Therefore, the 
orientation of each channel in the anomalous case is the same as that in the 
typical cases. The difference can be understood as a fundamental asymmetry in 





If the observed rectification is due to an asymmetric charge distribution  
in the channels, resulting in an asymmetric distribution of mobile ions, the 
asymmetric charge distribution in channels 2 and 3 in the anomalous case 
became more and less asymmetric than that in the typical cases, respectively. 
This shift of the rectification properties may be the consequence of an 
asymmetric surface potential. The model illustrated in Fig. 4.8 incorporates the 
finding that each channel is cation selective, so the wall of the channels is shown 
as containing fixed negative charges (2). For simplicity all the charge 
distributions within the channels are the same except that channel 2 has an 
orientation opposite to that if channels 1 and 3.  If the surface potential results 
in more negative surface charges on the bottom side of the membrane affecting 
each channel, this eliminates the electrical asymmetry of channel 1, and 3, and 
increases the electric asymmetry of channel 2. Therefore, the surface potential 
Figure 4.8. Surface potential changes the rectification of channels. Three 
cylindrical channels in a membrane are arranged in a row. The negative charges in 
each channel show the asymmetric distribution of charge in the channel. The middle 
channel (channel 2) has the opposite orientation with its adjacent channels. The 
cartoon shows the channels without the surface potential (A) or with the surface 






would make the rectification of channel 2 much greater in the anomalous case 
(i.e. with the asymmetric surface potential) as compared to the typical cases.  
 Another possibility that would result in an overall asymmetry and thus 
shift the measured rectification would be the presence of some modulating 
factor in the sample added to the chamber.  This factor could bind to the triplet 
resulting in the observed shift in rectification. 
Figure 4.9. Adaptation of channel 2 reopening. The conductance-voltage curve 
of channel 2 reopening (gray) was overlapped to that of channel 2 closing (black), 
which occurred later. A. Illustrates a case where channel 2 reopened to a state and 
stayed in that state until channel closure. B. Illustrates channel 2 reopening to a 
slightly more conductive state and transitioning to the more typical conducting state 





4.2.4 Adaptation of channel 2 
The experiments have shown signs of more complex behavior.  Indeed, 
some of the variability in the data could be attributed to channels entering 
somewhat different conformation when they transition between the open and 
closed state.  Some clear observations show that a channel may transition from 
a closed state to an open state that may not be the most stable state and then 
switch to the more typical conductance state by way of a small conductance 
change.  Two examples are illustrated in Fig. 4.7.  In panel A, the channel 
reopened and stayed in the same state, as far as can be discerned from the 
record, until it closed at negative potentials.  In panel B, channel 2 reopened to 
a slightly more conductive state with negative rectification and then underwent 
a change at high positive potentials to a state with slightly positive rectification, 
resembling that illustrated in panel A. It is likely that in the reopening process 
illustrated in panel B, channel 2 entered a higher energy state and then adapted 
to the lower energy state with time (Fig 4.7B). Such transitions were observed 
from time to time. 
4.3 Conclusion and Discussion 
4.3.1 Orientation of channel 2 is opposite to other channels 
Rectification probes the structure and dynamics of channels in their 
native state. It is different from other methods, such as mutations or chemical 
modifications, which may alter the structure or dynamics of the channel. 





negatively charged lipids or the inherent surface charges of the channel may 
influence to the rectification, it is clear that the rectification of channel 3 is 
different from that of channel 2 and is the same as that of channel 1. In addition, 
channel 2 closes at the same magnitude but different sign of voltage as 
compared to channel 3. This indicates the orientation of channel 1 and 3 are the 
same, but the orientation of channel 2 is antiparallel to other channels.  
Antiparallel orientation is rare in protein channels. A recently discovered 
fluoride ion channel, which is composed of an antiparallel homodimer, is an 
example of the same polypeptide inserting into a membrane in two opposite 
directions (137, 138). Typically, channel inserts into membranes in only one 
direction. However, the mitochondrial channel, VDAC, has been shown to 
insert into a planar membranes in both direction (139, 140). In addition, it is 
possible that the triple channel may insert into the membrane as a complex, 
instead of inserting into the membrane as an individual channel and forming a 
triplet channel later. Although it is possible the channel 2 is formed by a 
different protein from other channels, channel 2 and 3 have the same properties, 
including their conductance, cation selectivity and steepness of voltage 
dependence. Once the channel former is identified, we may be able to 
distinguish between these possibilities. 
4.3.2 Identification of the channel former 
The proteins responsible for forming the triplet channel were first 
present as a contamination of the isolation of the Bax protein. Originally, the 





using an affinity column and Bax is able to translocate to the MOM and formed 
channels to release IMS proteins. However, the triplet channel was still 
observed when the product was isolated from an E. coli strain without the Bax 
construct. The triplet channel is probably formed by a protein, instead of small 
molecules, such as peptides, because the sample (less than 20 mL) was dialyzed 
with an 8,000 MW cut-off dialysis membrane against 3 L and then 5 L of buffer. 
In any case, the channel former is minor, a minor constituent of the purified 
Bax fraction. Only a single band for Bax was observed on the silver-stained 
SDS-PAGE (~ 450 ng of protein was loaded). The isolated sample was sent to 
the Proteomics Core Facility at University of Maryland at College Park for 
analysis by mass-spectrometry-based proteomics to search for possible 
candidates of the channel former. The workflow was performed with trypsin 
digestion, reversed-phase liquid chromatography, linear ion trap-Orbitrap 
instrument, and MS/MS ions searching on the Mascot search engine. No 
suitable candidate was identified.   
4.3.2.1 Identify the cellular compartment in which the triplet resides 
Although the triplet channel was discovered in the soluble fraction (the 
cytosol fraction) of the cell lysate, it is still possible that the channel former 
arose from a membrane, either the inner or outer membrane. The channel 
former could also be secreted into the culture medium as an exotoxin. The 
culture medium was collected after the intact cells and cell debris are removed 
by centrifugation. Proteins were extracted from the inner and outer membranes 





n-laurylsarcosine (w/v) is used to extract the proteins from the inner membrane 
and then octyl-glucoside was used to extract those from the outer membrane 
(141). Each fraction was tested using the planar membrane technique to 
determine is the presence of the triplet channel. Our preliminary data indicated 
that the channel former is in the outer membrane.  
4.3.2.2 Testing whether the triplet channel is a porin 
The triplet channel is a three-channel unit.  It has a large conductance, 
1.5 nS in 1 M KCl.  That translates into a pore that is ~ 0.9 nm in diameter (94, 
136). These properties are similar to those of bacterial porins, located on the 
outer membrane. Table 4.3 shows the properties of each channel of the triplet 
and those of some porins. Although the properties of porins are well established, 
perhaps, however unlikely, experimental conditions may affect the results 
(142–144). Therefore, the major porins with similar properties were tested with 
our planar membrane setup. Neither OmpC nor OmpF showed the characteristic 
properties of the triplet channel, such as highly cooperativity and high voltage 
dependence. Instead the characteristic behavior of OmpC and OmpF were 
Table 4.3 Properties of some porins and the triplet channel.   
 
 Open channel 
conductance (nS) 
(in 1M KCl,) 
Selectivity (Po/Pa) 








1.5 3.6 0.9 3 
OmpC (156) 1.5 26 1.0 3 
OmpF (156) 2.1 3.6 0.7 or 1.2 3 







observed. Thus neither OmpC nor OmpF is responsible for the channel forming 
activity.  
4.3.2.3 Single- and multi- Porin knock outs 
Another way to search for the triplet channel former is by utilizing E. 
coli strains with single- or multi-porin knock-outs. In this way, if the gene of 
channel former was removed, the characteristic cooperative behaviors should 
not be observed and these behaviors should be observed if a construct with the 
gene is restored and expressed. E. coli BL21 (DE3) omp9 ΔlamB ompF::Tn5 
ΔompA ΔompC ompN::Ω, in which several genes of porin were either removed 
or interrupted, was used (141). Moreover, several candidates of the channel 
former obtained from a computational analysis were also tested. To conduct the 
computational analysis, protein BLAST was performed with known porins as 
query sequences, such as OmpF, OmpN, and ScrY, to find candidates. In 
addition, the candidates need to show channel structures by using the SWISS-
MODEL from ExPASY. The E. coli strains with corresponding single knock-
outs (ΔrhsD, ΔrhsE, ΔhtrE, or ΔflgE) were purchased from the Coli Genetic 
Stock Center. We found the triplet channel in all the knock-outs tested. The 
results demonstrate that LamB, OmpF, OmpA, OmpC, OmpN, RhsD, RhsE, 
HtrE, and FlgE are not the channel formers. 
4.3.3 Possible physiological role of the triplet channel 
The triple channel has not only a large single channel conductance and 





dependence and high cooperativity. These properties indicates that the triplet 
channel is (a) permeable to small molecules, such as metabolites, nutrients, and 
antibiotics, (b) very sensitive to changes in transmembrane potential and (c) 
highly regulated. These unprecedented properties most likely point to a highly 
regulated structure with critical physiological functions for E. coli. 
Because nonspecific porins reside in the outer membrane, typically it is 
impossible to establish transmembrane potential across the outer membrane 
based on maintenance of ion gradients or the use of ion pumps.  However, a 
Donnan potential does exist. The polyanionic oligosaccharides in the 
periplasmic space result in a Donnan potential, which is less than 30 mV (with 
100 mM of cation concentration in the bulk solution) (145, 146). This can close 
channels 2 or 3 depending on the sign and orientation.  Higher potentials would 
be present at lower ionic strengths. 
The similarity to the porins indicates that the physiological role of the 
triplet channel may be similar to that of the porins. Porins are involved in the 
facilitating the translocation of small molecules including antibiotics across the 
outer membrane (147, 148). Bacteria have developed several strategies to 
survive in the presence of antibiotics. For example, bacteria reduce the 
expression level of certain porins (149, 150), express mutated porins with lower 
permeability to antibiotics (151, 152), and raise the expression level of some 
efflux pumps (153, 154). Perhaps the triplet channel is involved in the process 
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